



Description

The present invention relates to tri-phenyl-alkane and alkene derivatives and their non-toxic pharmaceutically acceptable salts and esters, and their preparation, to pharmaceutical compositions containing the same and to their use.

The compounds of the present invention have the general formula:




or




30

35

wherein n is 0 to 4, R₁ and R₂, which can be the same or different, are H or OH; R₃ is H, OH, halogen, alkoxy of 1 to 4 carbon atoms, benzyloxy, methoxymethoxy, 2,3-dihydroxypropoxy or



wherein m is 1 or 2, R₆ and R₇, which can be the same or different are H or an alkyl group of 1 to 4 carbon atoms, or



50 can form an N-containing three-, four-, five- or six-membered heterocyclic ring; R₄ is OH, F, Cl, Br, I, mesyloxy, tosyloxy, formyloxy, alkylcarbonyloxy of 1 to 4 carbon atoms or CH₂R₄ is replaced by CHO; R₅ is H or OH; or R₄ and R₅ together form an —O— bridge between the carbon atoms to which they are attached, and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof provided that

55 (a) when n is 0, then R₂ and R₃ are not both simultaneously hydrogen.

(b) when n is 0, then R₃ must be other than halogen


(c) when n is 1 and R₄ and R₅ both are OH or together form an —O— bridge between the carbon atoms to which they are attached then R₁, R₂ and R₃ are not all simultaneously hydrogen.

60 (d) when n is 2 and R₄ and R₅ together form an —O— bridge between the carbon atoms to which they are attached, then R₁, R₂ and R₃ are not all simultaneously hydrogen.

A characteristic feature of the compounds of the invention is the functional group R₄ attached to the end of the alkyl side chain of the triphenylethene or the triphenylethane skeleton.


Compounds falling within this definition are mentioned in Chemical Abstracts 92:104639f and 94:58551n. However, the formulae given in these abstracts is incorrect; the journal references of these

65 abstracts make it clear that the formulae should be



Neither abstract contains any information which would enable the compound of the incorrect formula to be prepared or separated and accordingly this compound cannot be considered to be known in the art.

A preferred class of compounds of formula (I) or (II) are those wherein R_1 , R_2 and R_3 is hydrogen or hydroxy, at least one of R_1 , R_2 and R_3 being other than hydrogen, and R_3 may in addition be



where R_6 and R_7 are methyl or ethyl, R_4 is chlorine, bromine or hydroxy, R_5 is hydrogen or hydroxy, or R_4 and R_5 together form an —O— bridge between the carbon atoms to which they are attached, and in its non-toxic pharmaceutically acceptable salts and esters and mixtures thereof.

Preferred heterocyclic rings, when R_4 and R_5 together form an —O— bridge between the carbon atoms to which they are attached, are the tetrahydrofuran and tetrahydropyran rings. If



forms a heterocyclic ring, preferred radicals are for example aziridinyl, pyrrolidinyl, piperidino or morpholino radicals.

Preferred compounds of the invention are for example:

1-phenyl-1,2-bis(4-hydroxyphenyl)-1-buten-4-ol

4-bromo-1-phenyl-1,2-bis(4-hydroxyphenyl)-1-butene

2-phenyl-2,3-bis(4-hydroxyphenyl)tetrahydrofuran

1,2-diphenyl-1-(4-hydroxyphenyl)-1-penten-5-ol

2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydropyran

1,2-diphenyl-1-(4-hydroxyphenyl)-1-penten-5-al

1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol

2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydrofuran

1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol

4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene

4-chloro-1,2-diphenyl-1-[4-[2-(1-aziridinyl)ethoxy]phenyl]-1-butene

4-bromo-1,2-diphenyl-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-1-butene

2,3-diphenyl-2-[4-[2-(N,N-diethylamino)ethoxy]phenyl]tetrahydrofuran

1-phenyl-1,2-bis(4-hydroxyphenyl)butan-4-ol

4-bromo-1-phenyl-1,2-bis(4-hydroxyphenyl)butane

1,2-diphenyl-1-(4-hydroxyphenyl)butan-4-ol

4-chloro-1,2-diphenyl-1-[4-[2-piperidinoethoxy]phenyl]butane

1,2-diphenyl-1-(4-hydroxyphenyl)butane-1,4-diol

1-phenyl-1,2-bis(4-hydroxyphenyl)butane-1,4-diol

1,2-diphenyl-1-(4-methoxyphenyl)-1-buten-4-ol

4-bromo-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene

4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)butane

4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)-1-butene

1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-butane-1,4-diol

The invention encompasses pure (Z)- and (E)- isomers of the compounds and mixtures thereof as well as pure (RR, SS)- and (RS, SR)-enantiomer couples and mixtures thereof.

The invention includes pharmaceutically acceptable salts of aminosubstituted compounds with organic and inorganic acids, for example citric acid and hydrochloric acid. The invention also includes


quaternary ammonium salts, for example methiodide- and benzochloride salts, as well as N-oxides which can be prepared from the amino-substituted compounds.

Pharmaceutically acceptable salts can also be prepared from the phenolic compounds by treatment with inorganic bases, e.g. sodium hydroxide. Also esters of the phenolic compounds can be made with aliphatic and aromatic carboxylic acids, e.g., acetic acid and benzoic acid esters.


The compounds of the invention possess pharmacologically valuable properties because of their estrogenic, antiestrogenic or progestanic effects. Thus the compounds are useful for the purposes where such effects are desired.

The compounds of the invention are active against hormone-dependent tumours and are especially valuable in the treatment of breast tumours.


According to a feature of the invention, the compounds of formula (I) or (II) can be prepared by a process which, in general terms, comprises reacting a compound of the formula:



wherein n is as hereinbefore defined R'₁ is the same as R₁ as hereinbefore defined or is a hydroxyl group protected as a mixed acetal group, R'₄ is the same as R₄ as hereinbefore defined or is a protected such group, and R₉ is a group R₂ or R₃ as hereinbefore defined or is a hydroxyl group protected as a mixed acetal group, with an organic-metallic compound of the formula:




wherein M is —MgHal or —Li and R₁₀ is a group R₂ or R₃ as hereinbefore defined or is a hydroxyl group protected as a mixed acetal group, to give a compound of the formula:




which is then treated, if necessary, to convert the radicals R'₁, R'₄, R₉ and R₁₀ into the radicals R₁, R₂, R₃ and R₄ to provide a compound of formula II in which R₅ is hydroxyl, and optionally dehydrating the product to give a compound of formula I, or treating the product to provide a compound of formula II in which R₅ is other than hydroxyl, or one in which R₄ and R₅ together form an —O— bridge, and/or optionally treating the product to convert a radical R₁, R₂, R₃, R₄ or R₅ into another such radical as hereinbefore defined and/or optionally treating the product to convert it into a non-toxic pharmaceutically acceptable salt, N-oxide or ester thereof.


This process may be operated in a variety of ways. For example, a desoxybenzoin or desoxybenzoin derivative of the formula:



wherein R₁ and R₂, which can be the same or different, are as defined before or mixed acetal, for example (tetrahydropyran-2-yl)oxy, can be alkylated with a protected haloalcohol of the formula:



wherein hal is halogen, n is as defined before and OR₈ is either a mixed acetal, as (tetrahydropyran-2-yl)oxy, or benzyloxy to give a protected diphenyloxoalkanol of the formula




wherein R₁ and R₂ are as defined before or mixed acetal, R₈ and n are as above. The last mentioned compound is further reacted by a Grignard reaction with a phenylmagnesiumhalide derivative of the formula



or with a corresponding lithium compound of the formula




where R₃ in the compounds VI and VII is as defined before or a mixed acetal, as (tetrahydropyran-2-yl)oxy. This reaction gives a protected triphenyldiol of the formula




wherein R₁, R₂ and R₃ are as defined before or mixed acetal and R₈ and n are as above.

By interchange of the groups R₂ and R₃ of the intermediate (V) and the reagents (VI) or (VII) the same protected triphenyldiol is obtained. If OR₈ is a mixed acetal, the protecting group R₈ can be removed for example by an appropriate acid catalyst in the presence of water.


Simultaneously, any mixed acetal protecting group in a phenyl ring will be removed. The reaction gives a triphenyldiol of the formula



wherein R_1 , R_2 , R_3 and n are as defined before. The triphenyldiol (IX) is dehydrated for example by an appropriate acid catalyst, either in the presence of water or under dry conditions. Depending on the reaction conditions and the value of n , the reaction gives either a triphenylcyclo-oxa-alkane of the formula




or a triphenylalkenol of the formula



or a mixture thereof, wherein R_1 , R_2 , R_3 and n are as defined before.

By combining the removal of the protecting group and the dehydration, the triphenylcyclo-oxa-alkane (X) or the triphenylalkenol (XI) or a mixture thereof can be obtained in one single step from the protected triphenyldiol (VIII). By choice of appropriate conditions the triphenylalkenol (XI) can be obtained also from the triphenylcyclo-oxa-alkane (X). The benzyl group (R_3) is preferably removed from the protected triphenyldiol (VIII) by catalytic hydrogenation. Then by choice of suitable conditions, the same products (IX—XI) can be obtained as were obtained by removal of the mixed acetal group. Simultaneously a possible benzyl protecting group in the phenyl ring will be removed.

The removal of the protecting group from the protected triphenyldiol (VIII) and the dehydration can also be performed in the reverse order as follows: First the protected triphenyldiol (VIII) is dehydrated, for example with a mixture of acid anhydride and acid chloride to give a protected triphenylalkenol of the formula




wherein R_1 , R_2 and R_3 are as defined before or mixed acetal, and R_8 and n are as above. Then the mixed acetal or ether protecting group is removed as described above to give the triphenylalkenol (XI).


Desoxybenzoin or a desoxybenzoin derivative (III) can be alkylated also with an unprotected halcalcohol (IV) wherein R_8 is hydrogen, to give an unprotected diphenyloxoalkanol (V), wherein R_8 is hydrogen. In a further reaction the unprotected diphenyloxoalkanol (V) is reacted with a phenylmagnesiumhalide derivative (VI) or with a corresponding lithium compound (VII). This reaction gives an unprotected triphenyldiol (VIII), wherein R_8 is hydrogen. The same unprotected triphenyldiol is obtained by interchange

of the groups R_2 and R_3 of the intermediate and reagent. Dehydration, as well as the removal of a possible mixed acetal protecting group from the phenyl ring can be performed by an adaptation of the processes described above.

Another process for the preparation of the compounds of the invention comprises hydroalumination of a "styrene"-derivative of the formula




wherein R_1 is as defined before, n_1 is 0 to 3 and R_9 is $-\text{CHO}$, $-\text{CH}_2\text{OH}$, $-\text{COOH}$ or the corresponding ester, with an aluminium hydride reduction agent, for example lithium aluminium hydride, to give an Al-complex of the formula



where R_1 and n_1 are as defined before.


Reacting this complex with a benzophenone derivative of the formula




wherein R_2 and R_3 are the same as defined before gives, in one step, the triphenyldiol (IX). Reacting this with, for example, a carboxylic acid anhydride of the formula



wherein n is as above, or the corresponding carboxylic acid, results in esterification of the primary hydroxyl group, and gives a triphenyldiol ester of the formula




wherein R_1 , R_2 , R_3 and n are as defined before. This ester may then be dehydrated, for example with a carboxylic acid chloride, to give a triphenylester of the formula




wherein R_1 , R_2 , R_3 , and n are as defined before. Then the ester group is hydrolysed to give the triphenylalkenol (XI). Reacting the triphenyldiol (IX), the triphenyl-cyclo-oxa-alkane (X) or the protected or unprotected triphenyldiol (VIII), wherein OR_8 is a mixed acetal, benzyloxy or hydroxy, with an appropriate acid catalyst in a carboxylic acid containing 1 to 5 carbon atoms gives likewise the triphenylester (XVIII). Stronger reaction conditions simultaneously break a possible ether bond thus giving the corresponding phenol. The triphenylester (XVIII) can also be obtained for example by refluxing or warming the triphenylalkenol (XI) in a carboxylic acid of 1 to 5 carbon atoms.

Yet another process for the preparation of the compounds of the invention comprises dealkylation of an ether of the formula



wherein R_1 , R_2 , R_4 and n are as defined before and R_{10} is an alkyl or aralkyl group, to give the corresponding phenol or 4-hydroxyphenyl-diphenylalkene of the formula




wherein R_1 , R_2 , R_4 and n are as defined before. In the same way the cleavage of ether bonds from the other two phenyl groups can be performed. Further several more ether bonds can simultaneously be broken to give bis- or trisphenols.


Yet another process for the preparation of the compounds of the invention comprises alkylation of the 4-hydroxyphenyl-diphenylalkene (XX) for example either with diazomethane or in alkaline conditions with an alkylhalide derivative of the formula



wherein R_{11} is an alkyl group of 1 to 4 carbon atoms, benzyl, methoxymethyl, 2,3-dihydroxypropyl or




wherein R_6 , R_7 and m are as defined before, to give a triphenylalkene-ether of the formula



wherein R_1 , R_2 , R_4 , R_{11} and n are as defined before. Simultaneously one or more phenolic OH-groups can be alkylated to give mono-, bis- or tris-ethers. The 4-hydroxyphenyl-diphenylalkene (XX) can also be alkylated with a dihaloalkane of the formula




wherein m is as defined before and hal are halogen atoms, which can be the same or different. This gives a 4-(haloalkoxy)phenyl-diphenylalkene of the formula



wherein R_1 , R_2 , R_4 , n , m and hal are as defined before. This compound is reacted with an amine of the formula




wherein R_6 and R_7 are as defined before, to give a (4-aminoalkoxy)phenyl-diphenylalkene of the formula




wherein R_1 , R_2 , R_4 , R_6 , R_7 , m and n are as defined before.

The preparation of the saturated phenols corresponding formula (II) by dealkylating and the alkylations of them can be performed in the same way as described above for the unsaturated phenols corresponding to formula (I) (see formulae XIX—XXVI).


5 Another method for the preparation of the compounds of the invention comprises converting the triphenylalkenol (XI) by various methods into a triphenylhalide of the formula




or by reacting it with, for example, sulfonic acid chloride to give the corresponding triphenylsulfonate of the formula



50 wherein R_1 , R_2 , R_3 and n are as defined before, hal is halogen and R_{12} is methyl or 4-tolyl. Accordingly, the triphenyldiol (IX) can be converted either to the triphenylhydroxylhalide of the formula



or to a triphenylhydroxysulfonate of the formula




wherein R_1 , R_2 , R_3 , R_{12} , n and hal are as defined before. Dehydration of the triphenylhydroxyhalide (XXIX) and the triphenylhydroxysulfonate (XXX) gives the corresponding triphenylhalide (XXVII) and triphenylsulfonate (XXVIII). Furthermore, the triphenylhalide (XXVII) can also be obtained in one single reaction step from the triphenyldiol (IX) as well as from the triphenylcyclo-oxa-alkane (X). For example by treating the triphenyldiol (IX) with thionyl chloride the triphenylchloride (XXVII, $\text{hal}=\text{Cl}$) is obtained. The halides (XXVII) can also be prepared from the corresponding sulfonates (XXVIII) or from other halides (XXVII).

Desoxybenzoin or a desoxybenzoin derivative (III) can be alkylated also with a dihaloalkane of the formula




wherein n is as defined before and hal are halogen atoms, which can be the same or different, to give a diphenyloxohalide of the formula




wherein R_1 and R_2 are as defined before or mixed acetal, hal and n are as above. In a further reaction the diphenyloxohalide (XXXII) is reacted with a phenylmagnesiumhalide derivative (VI) or with a corresponding lithium compound (VII). This reaction gives a triphenylhydroxyhalide (XXIX), wherein R_1 , R_2 and R_3 are as defined before or mixed acetal, hal and n are as above. The same diphenylhydroxyhalide is obtained by interchange of the groups R_2 and R_3 of the intermediate and reagent. The removal of the possible mixed acetal protecting group from the phenyl ring gives the triphenylhydroxyhalide (XXIX). By combining the removal of the possible protecting group and the dehydration the triphenylhalide (XXVII) can be obtained in one single step from triphenylhydroxyhalide (XXIX), wherein R_1 , R_2 and R_3 are as defined before or mixed acetal, hal and n are as defined above.

Yet another method for the preparation of the compounds of the invention comprises converting a triphenylhalide of the formula




wherein R_1 , R_2 , R_3 and n are as defined before, and X is halogen, to the corresponding Grignard-complex or lithium salt (XXXIII) wherein X is MgX or Li , respectively. Reacting this complex or salt with formaldehyde, ethylene oxide or trimethylene oxide gives a triphenylalkenol (XI) wherein n is 1 to 4.

Reacting a triphenylhalide (XXVII) or a triphenylsulfonate (XXVIII) wherein n is 0 to 3, with a cyano group gives a triphenyl nitrile of the formula




wherein R_1 , R_2 , R_3 and n_1 are as defined before. Hydrolysis of this compound gives the corresponding triphenylcarboxylic acid of the formula



wherein R_1 , R_2 , R_3 and n_1 are as above. The triphenylcarboxylic acid (XXXV) can be reduced either in one step or for example via an ester intermediate to give a triphenylalkenol (XI) wherein n is 1—4.

According to another method the Grignard-complex or the lithium salt (XXXIII) is reacted with carbon dioxide to give a triphenylcarboxylic acid of the formula




wherein R_1 , R_2 , R_3 and n are as above. The compound (XXXVI) is reduced to the triphenylalkenol (XI) as described before.

Another method for the preparation of the compounds of the invention is the alkylation of desoxy-


benzoin derivative (III), with an alkylating agent consisting of an acetal- or mixed acetal-protected haloaldehyde of the formula



wherein n is as above and R_{13} and R_{14} , which can be the same or different, are for example alkyl groups, e.g. ethyl groups, or may be linked, and may then form together a 1,3-propylene group. The reaction product obtained is a protected diphenyloxaldehyde of the formula




wherein R_1 and R_2 are as before or mixed acetal, and R_{13} , R_{14} and n are as above. The compound (XXXVIII) is then reacted with a phenylmagnesiumhalide (VI) or the corresponding lithium compound (VII). The reaction gives a protected triphenylhydroxyaldehyde of the formula




wherein R_1 , R_2 and R_3 are as before or mixed acetal and R_{13} , R_{14} and n are as above.

By interchange of the groups R_2 and R_3 of the intermediate (XXXVIII) and the reagents (VI) or (VII), the same protected triphenylhydroxyaldehyde (XXXIX) is obtained. The protecting group can be removed for example by an appropriate acid catalyst in the presence of water. In the same step a possible mixed acetal protecting group attached to the phenyl ring will be removed. This results, depending on the value of n , either in a triphenylhydroxyaldehyde (XXXXa), the corresponding cyclic hemiacetal (XXXXb), or in a mixture thereof




wherein R_1 , R_2 , R_3 and n are as defined before.

Dehydration of the compound (XXXXa) or the corresponding compound (XXXXb) or a mixture thereof results in a triphenylaldehyde of the formula




wherein R_1 , R_2 , R_3 and n are as defined before. On the other hand, dehydration of a protected triphenylhydroxyaldehyde (XXXIX) results in a protected triphenylaldehyde of the formula



wherein R_1 , R_2 and R_3 are as defined before or mixed acetal, and R_{13} , R_{14} and n are as above. The protecting group is removed as above, after which the triphenylaldehyde (XXXXI) is obtained. The triphenylaldehyde (XXXXI) can further be obtained by oxidation of the triphenylalkenol (XI) or by reduction of the triphenylcarboxylic acid (XXXVI) either in a single step or via an intermediate.

The triphenylaldehyde (XXXXI) can be dealkylated and alkylated in the same way as the alcohols (see formulae XIX—XXVI) as described before.

The triphenylalkane compounds of the invention can be prepared by catalytic hydrogenation of the triphenylalkene derivative (I) wherein R_1 , R_2 , R_3 , R_4 and n are as defined before, or a triphenylalkane derivative (II), wherein R_1 , R_2 , R_3 , R_4 , R_5 and n are as defined before except that R_5 is other than hydrogen, to give the corresponding triphenylalkane derivative of the formula



wherein R_1 , R_2 , R_3 , R_4 and n are as defined before. The triphenylalkane derivatives (XXXXIII) can be converted in the same way as the corresponding triphenylalkene derivatives as described before. Such conversion reactions are for example dealkylation of the phenyl ethers, alkylation of the phenols, preparation of halides and sulfonates, extension of the side chain, and reduction and oxidation reactions.

When the product is a compound of formula I or another triphenylalkene derivative containing a double bond, a mixture of the (Z)- and (E)-isomers is obtained. By choice of appropriate reaction conditions, an isomer mixture enriched in respect of one or the other of the isomers can be obtained. The reaction

conditions can also be chosen so that equal amounts of the isomers are formed.

For example, when a protected diphenyloxoalkanol (V) is reacted by a Grignard reaction with phenyl-magnesiumhalide derivative (VI) either the (RR,SS)- or the (RS,SR)-enantiomer pair is obtained, due to asymmetrical induction. Interchanging R_2 and R_3 between the starting material and the reagent results in the opposite enantiomer pair.

Reacting the aluminium complex of formula (XIV) with the benzophenone derivative (XV) gives equal amounts of the (RR,SS)-triphenyldiol (IX).

The preparation of triphenylcyclo-oxa-alkanes from triphenyldiols (IX) gives almost only the (RR,SS)-pair starting from the (RR,SS)-pair, and a mixture of the (RS,SR)- and (RR,SS)-pairs starting from the (RS,SR)-pair.

The preparation of the triphenylalkane derivative (II), wherein R_5 is H, from the triphenylalkene derivative (I) by catalytic hydrogenation gives the (RR,SS)-enantiomer pair from the (Z)-isomer and the (RS,SR)-enantiomer pair from the (E)-isomer.

The alkylation of phenols generally gives the pure isomer or enantiomer pair from the corresponding pure isomer or enantiomer pair, although some isomerisation may occur depending on the conditions used. A mixture of starting materials naturally results in a corresponding mixture of products.

Conversion of the functional group at the end of the alkane or the alkene chain gives in most cases the pure isomer or enantiomer pair from the corresponding pure isomer or enantiomer pair. Mixtures give of course the corresponding mixtures.

The pure (Z)- and (E)-isomers as well as the pure (RR,SS)- and (RS,SR)-enantiomer pairs can be isolated from a mixture of the isomers either by fractional crystallization, fractional dissolution, chromatographically or by a combination thereof. The pure (Z)- and (E)-isomers of the amines as well as the (RR,SS)- and (RS,SR)-enantiomer pairs can be isolated from the mixture of the isomers both when the compounds are free bases and when they are in salt form.

Accordingly the isomers and enantiomers of the phenols can be isolated both when the phenols are free "acids" and when they are in the salt form.

The salts of the amines are prepared by reacting the amines with organic or inorganic acids, for example citric acid or hydrochloric acid.

The quaternary ammonium salts are obtained by reacting the amines with alkylating agents, for example methyl iodide or benzyl chloride. The N-oxides are prepared by reacting the amines with a suitable oxidizing agent, for example hydrogen peroxide.

The salts of the phenols are obtained by reacting the phenols with inorganic bases, for example sodium hydroxide. Furthermore, esters of the phenols are obtained by reacting the phenols with an aliphatic or aromatic carboxylic acid, the corresponding acid chloride or acid anhydride.

As stated herein above, the compounds of the general formula (I) and (II) and their non-toxic, pharmaceutically acceptable salts and esters and N-oxides exhibit valuable pharmacological properties and in particular hormonal properties as oestrogenic and anti-oestrogenic agents (depending upon the dosage used). They also show progestanic and anti-tumour activity, in particular against hormone-dependent, and especially oestrogen-dependent, tumours.

Administration of the compounds of formula (I) and (II), their non-toxic, pharmaceutically acceptable salts or esters or mixtures thereof may be achieved parenterally, intravenously or orally. Typically, an effective amount of the derivative is combined with a suitable pharmaceutical carrier. As used herein, the term "effective amount" encompasses those amounts which yield the desired activity without causing adverse side-effects. The precise amount employed in a particular situation is dependent upon numerous factors such as method of administration, type and size of mammal, condition for which the derivative is administered, etc., and of course the structure of the derivative.

The pharmaceutical carriers which are typically employed with the compounds of the present invention may be solid or liquid and are generally selected with the planned route of administration in mind. Thus, for example, solid carriers include lactose, sucrose, gelatin and agar, while liquid carriers include water, syrup, peanut oil and olive oil. Other suitable carriers are well-known to those skilled in the art of pharmaceutical formulations. The combination of the derivative and the carrier may be fashioned into numerous acceptable forms, such as tablets, capsules, suppositories, solutions, emulsions, and powders.

The affinity of the new compounds for oestrogen receptors was determined by the ability to compete with ^3H -labelled 17- β -estradiol in rat uterus cytosol preparation. After incubation, receptor-bound and receptor-unbound ligands were separated by a known dextrancharcoal method. (Korenman, S. G.: "Comparative binding affinity of estrogens and its relation to oestrogenic potency". Steroids 13: 163-177, 1969).

The oestrogen-antiestrogen (progesterone) effect of the new compounds *in vivo* was determined as follows:

(1) The oestrogenic properties were determined by administering the new compounds, suspended in sesame oil, subcutaneously to 21 days old immature mice on three consecutive days. The mice were killed on the fourth day and the uterus was weighed. Estradiol (positive control) increases the weight of the uterus. The weight correlates with the oestrogenic effect of the compound tested.

(2) the antiestrogenic effects of the new compounds were determined in a similar manner in immature

mice. In this case, the ability of the molecules to inhibit oestrogen-induced uterus weight increase was also investigated.

The progestanic effects of the new compounds were studied in a similar manner to the oestrogenic effects. Medroxy-progesterone acetate, which decreases uterus weight, was used as reference.

5 The anti-tumour effect was studied *in vitro* as follows:

The growth of MCF-7 cell line (human mammary adenocarcinoma, known to be oestrogen-dependent) was evaluated in the presence or absence of estradiol, medroxyprogesterone acetate or the compound to be investigated. Combinations of compound under test plus estradiol or medroxyprogesterone were also studied. The amount of living cells after 4 h, 24 h and 48 h incubations were
10 determined by bioluminescence assay (intracellular ATP determination).

The anti-tumour effect was investigated *in vivo* against DMBA-induced rat mammary adenocarcinomas, transplantable mammary and ovarian adenocarcinoma and transplantable prostatic squamous cell carcinoma by the following methods:

Mammary adenocarcinomas were induced by DMBA in 35-40 days old female rats. Treatment with
15 the compound under test was started after palpable tumours had appeared. Tumour size and numbers of tumours were evaluated twice a week. Tumour sizes in the control group, treated with solvent, were compared with the test groups.

The activity of the molecules against other tumours was studied by administering the molecules by stomach tube to animals implanted with transplantable uterus sarcoma (mice) or prostatic adenocarcinoma (rats).
20

Daily or twice weekly administration schedules were employed. NMRI mice (about 20 g, females) and Fischer 344 rats (about 200 g, males) were used. Estramustine phosphate served as positive control.

Transplantable rat mammary adenocarcinoma was developed by inoculating pieces of DMBA-induced carcinomas subcutaneously to healthy mature female rats. A tumour which expressed malignant growth
25 was selected for further transplantations. Other transplantable tumours were inoculated subcutaneously as washed cell suspension (10^7 cells/animal).

The compounds of the invention possessed good affinities to estrogen receptors as measured by the dextran-charcoal method. The results are shown in table 1 as follows:

30

35

40

45

50

55

60

65

TABLE 1

5	affinity	concentration of compound where 50% competition (inhibition) with ^3H -estradiol occurred
	+++	10^{-6}M (inhibition)— 10^{-7}M (weak affinity)
	++	10^{-5}M (inhibition)— 10^{-6}M (weak affinity)
	+	10^{-4}M (inhibition)— 10^{-5}M (weak affinity)
	±	10^{-4}M no clear inhibition

10 Estrogen receptor affinities of certain compounds of formulae (I) and (II)
Investigated compound

15	No.	Name	Affinity
	1.	1,2-diphenyl-1-(4-hydroxyphenyl)-butane-1,4-diol, (RR,SS)-enantiomer pair	++
	2.	2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydrofuran, (RR,SS)-enantiomer pair	+++
20	3.	1,2-diphenyl-1-(4-methoxyphenyl)-1-buten-4-ol	++
	4.	1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol, (Z)-isomer	++
	5.	2,3-diphenyl-p2-(4-hydroxyphenyl)tetrahydropyran (RR,SS)-enantiomer pair	+++
25	6.	1,2-diphenyl-1-(4-hydroxyphenyl)-1-penten-5-ol (Z,E)-isomers	++(+)
	7.	4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol, (Z)-isomer	+++
	8.	1-phenyl-1,2-bis(4-hydroxyphenyl)-butane-1,4-diol	++
	9.	2-phenyl-2,3-bis(4-hydroxyphenyl)tetrahydrofuran	+++
30	10.	1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol, (E)-isomer	+++
	11.	1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol (Z)-isomer	++
	12.	1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol (E)-isomer	+
	13.	4-bromo-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol, (Z)-isomer	+++
35	14.	4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)butane (RR,SS)-enantiomer pair	+++
	15.	4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol (Z)-isomer	++
	16.	2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-tetrahydrofuran (RR,SS)-enantiomer pair	+
40	17.	1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butane-1,4-diol (RR,SS)-enantiomer pair	+
	18.	4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol (E)-isomer	+

45 The estrogenic effect of compounds of formula (I) and (II) as measured by their ability to increase the weight of immature mouse uterus was always far less than that of estradiol, the positive control. The estrogenic effect of the compounds 5, 7, 13 and 14 could be seen only at the higher concentrations investigated. At the dose of 5 mg/kg the effect of the first was 41% less than that of estradiol 0.05 mg/kg. The corresponding values for the latter compounds were about 50%. The compounds 4 and 11 and compounds 2, 16 and 17 possessed no estrogenic effects of their own up to doses of 5 mg/kg.

50 The compounds 4, 7 and 11, 13, 14 and 15 possessed anti-estrogenic effects as measured by their ability to inhibit estradiol induced weight increase in immature mouse uterus. Compounds 4 and 7 caused at the dose of 0.5 mg/kg, and compounds 11, 13, 15 and 14 at the dose of 5 mg/kg, a 12%, 27%, 31%, 25%, 25% and 20% inhibition of estradiol induced effect in mouse uterus respectively.

55 The progestanic effects of the compounds were measured as described earlier. Medroxyprogesterone acetate, the positive control, caused up to 40% inhibition in the weight of immature mouse uterus. The effects of compound 2 could purely be considered to be due to its progestanic effect. It had no antiestrogenic or estrogenic effect of its own up to 5 mg/kg. At the dose of 0.05 mg/kg the weight of mouse uterus was decreased by 50% and a synergistic effect with medroxyprogesterone was seen.

60 The compounds 4 and 11 given alone could cause a 38% and 56% reduction respectively in the weight of mouse uterus, an effect which could in part be considered to be due to their antiestrogenic effects. Compound 11 was found to possess a synergistic effect with medroxy-progesterone and compound 4 caused a slight inhibition, yet a 17% reduction in the weight of uterus was seen. Compound 5 of formula (II)

had no antiestrogenic effect and could decrease the weight of uterus by 34% (0.05 mg/kg) due to its progestanic effect. No inhibition of medroxyprogesterone was seen at that dose. With increased doses, however, a weak estrogenic effect could be seen which effect overcame that of medroxyprogesterone. A slight increase in the weight of uterus was achieved. Compound 7 besides possessing antiestrogenic and estrogenic properties was found to be progestanic and cause slight inhibition of medroxyprogesterone at the lowest dose studied.

In tables 2A and 2B a summary of the estrogenic/antiestrogenic and progestanic effect can be seen. The percentages refer to increase/reduction in the weights of mice uterus.

The antitumour effects of compounds of formula (I) and (II) have been tested *in vitro* against MCF—7 human mammary adenocarcinoma cell line and *in vivo* against DMBA-induced rat mammary adenocarcinomas, rat ovarian carcinoma, rat prostatic carcinoma and mouse uterus sarcoma.

On table 3 the antitumour effects of certain compounds of formula (I) and (II) can be seen. The results are shown as follows:

15	effect	IC ₅₀ = concentration of compound where 50% inhibition of cell growth could be seen.
	+++	10 ⁻⁶ — 5 × 10 ⁻⁶ M
	++	5 × 10 ⁻⁶ — 10 ⁻⁵ M
20	+	10 ⁻⁵ — 5 × 10 ⁻⁵ M
	-	5 × 10 ⁻⁵ M

TABLE 2A

Summary of estrogenic/antiestrogenic and progestanic effects of compounds of formula (I) and (II)

30	Given	2	4	5	7	11
	alone	progestanic 50% reduction	anti-estrogenic progestanic 31% reduction	progestanic 34% reduction	estrogenic progestanic	anti-estrogenic 56% reduction
35	with estradiol 0.05 mg/kg	no synergism or inhibition	anti-estrogenic 21% reduction	no synergism or inhibition	anti-estrogenic 27% reduction	anti-estrogenic 31% reduction
40	with medroxy- progesterone 0.06 mg/kg	synergistic effect 53% reduction compared to control	weak inhibition 17% reduction compared to control	no inhibition 34% reduction	weak inhibition 14% reduction compared to control	no inhibition 40% reduction

TABLE 2B

Summary of estrogenic/antiestrogenic and progestanic effects of compounds of formula (I) and (II)

50	Given	14	15	9	13	18
	alone	estrogenic 50% increase	estrogenic 20% increase	estrogenic 50% increase	estrogenic 50% increase	estrogenic 20% increase
55	with estradiol 0.05 mg/kg	anti-estrogenic 20% reduction	anti-estrogenic 25% reduction	not anti- estrogenic <10% reduction	anti-estrogenic 25% reduction	not anti- estrogenic <10% reduction
60	with medroxy- progesterone 0.06 mg/kg	Not tested	Not tested	Not tested	weak inhibition 14% reduction compared to control	no effect

TABLE 3
The antitumour effect of certain compounds of
formula (I) and (II) against MCF—7 cell line

Investigated Compound	Antitumour effect
4	+++
5	+++
7	+++
12	+++
13	+++
18	+++
2	++
14	++
15	++
16	++
6, (E)-isomer	++

As can be seen the compounds tested were very effective *in vitro* against MCF—7 mammary cells and by increasing the concentration the death of the cell line was achieved with every compound.

The antitumour effect *in vivo* of compounds 4 and 7 has been tested against DMBA-induced rat mammary adenocarcinoma. At the dose 10 mg/kg of compound 4 the growth rate of tumours was slowed to one eighth compared to that of the controls. The antitumour effect of compound 7 had been found at the dose range of 1.0—30 mg/kg. At the highest dose used the growth of the tumours was found to stop (table 4).

TABLE 4
The size and growth of DMBA induced tumours during treatment
with compound 7 compared with the control group

Day of treatment	Control size of tumour	growth	Compound 7 30 mg/kg size of tumour	growth
1	3.914	0	1.5188	0
3	4.716	0.803	1.6739	0.1551
7	8.509	4.596	1.3070	-0.2118
9	11.622	7.708	1.0474	-0.4714
14	16.176	12.262	0.1179	-0.5392
17	17.473	12.826	0.0820	-0.5752
21	22.695	18.049	0.0721	-0.5851
25	29.542	24.896	0.0891	-0.5682
28	35.115	30.469	0.09316	-0.5640
35	32.803	28.156	0.1193	-0.5379

The size refers to the width × height of the tumour. The growth rate is a difference between sizes compared with that of the first day of the treatment. Antitumour effect less than that of compound 7 against DMBA-induced mammary cancer was observed with the compounds 2, 12 and 13.

The effect of compound 7 against rat ovarian carcinoma and mouse uterus sarcoma had been tested against transplantable tumours using methods described earlier. After two weeks' treatment with 100 mg/kg, the size of the uterus sarcoma was 30% smaller than that of control and after ten days' treatment with 5 mg/kg, the size of rat ovarian carcinoma was 20% smaller compared with the control.

The effect of compound 2 against transplantable prostatic carcinoma was measured as described earlier. The size of the tumour after 12 days' treatment with compound 2 (1 mg/kg) was 29% smaller than that of the control.

Acute toxicity, LD₅₀ p.o. in mice, varies from 1000 to 3200 mg/kg for the compounds tested. The clinical dosage ranges for oral administration may vary from 10 to 200 mg per day for an adult person.

The following Examples illustrate the invention.

The ¹H NMR spectra were measured in on a Perkin-Elmer R 24A or a Bruker WP 80 DS instrument using TMS as internal reference (Chemical shifts in δ , ppm). The letters s, d, t and m are used to indicate a singlet, doublet, triplet or multiplet, respectively. In the same connection, the number of hydrogen atoms is also stated. Mass spectra were recorded by Kratos MS 80 RF using direct inlet and 70 ev ionization voltage.

Example 1

a) 4-[(tetrahydropyran-2-yl)oxy]-1,2-diphenylbutan-1-one

A mixture containing 19.6 g of desoxybenzoin, 20.9 g of tetrahydropyran-2-yl ester-protected bromoethanol, 1.0 g of TEBAC (triethylbenzylammonium chloride) and 50 ml of 48% sodium hydroxide solution is stirred for 2 h at 75°C. Water is added and the product extracted in toluene. The toluene solution is washed with water and dried over sodium sulfate. Finally the solvent is evaporated. The yield is quantitative, but the oily product contains about 20% O-alkylation product.

b) 4-[(tetrahydropyran-2-yl)oxy]-1,1,2-triphenylbutan-1-ol.

First a Grignard complex is prepared under dry conditions by allowing 3.6 g of magnesium turnings in 25 ml of dry tetrahydrofuran to react with 23.6 g of bromobenzene in 50 ml of dry tetrahydrofuran. Then the evaporation residue obtained in step (a) in 75 ml of dry tetrahydrofuran is added. The reaction mixture is refluxed for 2 h. The cooled mixture is poured into a saturated solution of ammonium chloride. After shaking, the organic layer is separated. The extraction is repeated with ether. Then the organic layers are combined and dried over sodium sulfate. Finally the solvent is evaporated.

c) 1,1,2-triphenylbutane-1,4-diol.

The evaporation residue obtained in step (b) is dissolved in a mixture containing 400 ml of absolute ethanol, 10 g of concentrated sulfuric acid and 75 ml of water. The mixture is stirred for 2 h at room temperature. The solution is neutralized with 2 M sodium hydroxide solution, after which the ethanol is evaporated. Water is added to the residue. Then the product is extracted in ethyl acetate. The ethyl acetate solution is dried over sodium sulfate, and the solvent is evaporated. The product is recrystallized from toluene. The yield is 16.5 g (52% from desoxybenzoin) and m.p. 185—7°C.

¹H-NMR-spectrum (CD₃OD): δ 2.06 (2H, q), 3.33 (2H, t), 3.92 (1H, t), 4.76 (2H, s), 6.85—7.45 (13H, m), 7.68 (2H, dd).

Example 2

2,2,3-triphenyltetrahydrofuran.

31.8 g of 1,1,2-triphenylbutane-1,4-diol obtained as described in Example 1(c) are dissolved in a mixture containing 400 ml of absolute ethanol, 10 ml of concentrated sulfuric acid and 75 ml of water. Then the mixture is stirred for 3 h at 45°C. The solution is neutralized with 2 M sodium hydroxide solution, after which the ethanol is evaporated. Water is added into the residue and the product is extracted in toluene. The toluene solution is dried over sodium sulfate, and the solvent is evaporated. Recrystallization is performed from ethanol. The yield of the product is 26.4 g (88%) and m.p. 112—3°C.

¹H-NMR-spectrum (CDCl₃): δ 1.90—2.60 (2H, m), 3.85—4.55 (3H, m), 6.90—7.45 (13H, m), 7.63 (2H, dd).

Example 3

a) 4-acetoxy-1,1,2-triphenyl-1-butene

30.0 g of 2,2,3-triphenyltetrahydrofuran are dissolved in 125 ml of acetic acid, after which 25 ml of 40% hydrogen-bromide in acetic acid are added. The mixture is stirred for 1 h at 75°C. The solvent is evaporated, and 1 M sodium carbonate solution is added in excess. The product is extracted in toluene. The toluene solution is dried over sodium sulfate and the solvent is evaporated. The product is recrystallized from aqueous methanol and then has m.p. 81—3°C. The yield is 28.7 g (84%).

¹H-NMR-spectrum (CDCl₃): δ 1.82 (3H, s), 2.78 (2H, t), 4.02 (2H, t), 6.85 (5H, s), 7.02 (5H, s), 7.21 (5H, s). MS: m/z 342 (M⁺, 5), 282 (64), 205 (28), 191 (100), 167 (27), 91 (70).

b) 1,1,2-triphenyl-1-buten-4-ol

34.2 g of 4-acetoxy-1,1,2-triphenyl-1-butene are dissolved in 200 ml of 94% ethanol, after which 20 ml of water and 45 ml of a 20% sodium hydroxide solution are added. The mixture is refluxed for 1 h. The solution is neutralized with 2 M hydrochloric acid, after which the ethanol is evaporated. Water is added into the residue. The product is extracted in ethyl acetate, the ethyl acetate solution is dried over sodium sulfate and the solvent is evaporated. The product is recrystallized from a mixture of water and methanol and then has m.p. 117—9°C. The yield is 23.7 g (79%).

¹H-NMR-spectrum (CDCl₃): δ 1.34 (1H, s), 2.73 (2H, t), 3.05 (2H, t), 6.90 (5H, s), 7.11 (5H, s), 7.25 (5H, s).

c) 4-tosyloxy-1,1,2-triphenyl-1-butene

The reaction is performed under dry conditions. 30.0 g of 1,1,2-triphenyl-1-buten-4-ol are dissolved in 100 ml of dry pyridine. Then with stirring and cooling the mixture on ice, 57.0 g of 4-toluenesulfonic acid chloride in 50 ml of dry pyridine are added dropwise to the mixture. The mixture is stirred for 6 h at 0°C. Then 250 ml of ice-cold water and 750 ml of cold 2 M hydrochloric acid are added. The precipitate is collected by filtration and washed with water. Finally the product is recrystallized from ethanol. The yield is 36.8 g (81%) of a product having m.p. 137–9°C.

¹H-NMR-spectrum (CDCl₃): δ 2.32 (3H, s), 2.77 (2H, t), 3.92 (2H, t), 6.86 (5H, s), 6.98 (5H, s), 7.16 (2H, d), 7.21 (5H, s), 7.60 (2H, d).

Example 4

a) 4-[(tetrahydropyran-2-yl)oxy]-2-phenyl-1-(4-methoxyphenyl)butan-1-one

The compound is prepared from 22.6 g of 4-methoxydesoxybenzoin and 20.9 g of tetrahydropyran-2-yl ether-protected bromoethanol according to the procedure described in Example 1(a).

b) 4-[(tetrahydropyran-2-yl)oxy]-1,2-diphenyl-1-(4-methoxyphenyl)butan-1-ol (RR,SS and RS,SR)

The (RR,SS)-isomers are prepared from the evaporation residue obtained in Example 1 step (a) and 28.1 g of 4-bromoanisole using the procedure described in Example 1(b).

The (RS,SR)-isomers are prepared from the evaporation residue obtained in step (a) and 23.6 g of bromobenzene in the same manner as (RR,SS)-isomers above.

c) 1,2-diphenyl-1-(4-methoxyphenyl)butane-1,4-diol (RR,SS and RS,SR)

The (RR,SS)-isomers are prepared from the evaporation residue of (RR,SS)-isomers obtained in step (b) according to the procedure described in Example 1(c). The product is recrystallized from toluene. The yield is 13.9 g (40% from desoxybenzoin) and the product has m.p. 124–6°C.

¹H-NMR-spectrum (CD₃OD): δ 2.06, (2H, q), 3.32 (2H, t), 3.77 (3H, s), 3.84 (1H, dd), 4.78 (2H, s), 6.80–7.25 (12H, m), 7.56 (2H, d).

The (RS,SR)-isomers are prepared from the evaporation residue of (RS,SR)-isomers obtained in step (b) in the same manner as the (RR,SS)-isomers above. The product is recrystallized from toluene. The yield is 16.0 g (46% from 4-methoxydesoxybenzoin) and the m.p. of the product is 172–4°C.

¹H-NMR-spectrum (CD₃OD): δ 2.03 (2H, q), 3.32 (2H, t), 3.63 (3H, s), 3.86 (1H, t), 4.75 (2H, s), 6.54 (2H, d), 6.95–7.45 (10H, m), 7.65 (2H, dd).

Example 5

2,3-diphenyl-2-(4-methoxyphenyl)tetrahydrofuran (RR,SS and RS,SR)

The (RR,SS)-isomers are prepared from the evaporation residue of (RR,SS)-isomers obtained in Example 4(b) according to the procedure described in Example 2. The product is recrystallized from isopropanol. The yield is 16.2 g (49% from desoxybenzoin) and the product has m.p. 116–8°C.

¹H-NMR-spectrum (CDCl₃): δ 1.90–2.60 (2H, m), 3.77 (3H, s), 3.80–4.50 (3H, m), 6.85 (2H, d), 7.02 (10H, s), 7.52 (2H, d).

MS: m/z 330 (M⁺, 13), 212 (85), 135 (87), 118 (93), 117 (100), 100 (44), 91 (42), 77 (50).

The (RS,SR)-isomers are prepared from 34.8 g of (RS,SR)-1,2-diphenyl-1-(4-methoxyphenyl)butane-1,4-diol in the same manner as (RR,SS)-isomers above, after which a mixture of (RS,SR)- and (RR,SS)-isomers is obtained. The evaporation residue is recrystallized from isopropanol. The precipitate consisting of (RR,SS)-isomers is removed by filtration. The mother liquor is evaporated and the evaporation residue is recrystallized from methanol. The yield of the product is 4.6 g (14%) having m.p. 74–6°C.

¹H-NMR-spectrum (CDCl₃): δ 1.95–2.60 (2H, m), 3.64 (3H, s), 3.80–4.55 (3H, m), 6.54 (2H, d), 6.90–7.45 (10H, m), 7.59 (2H, dd).

Example 6

a) 1,2-diphenyl-1-(4-methoxyphenyl)-1-butan-4-ol (Z and E)

(Z)-isomer: (Z)-1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol (see Example 13a) is dissolved in methanol, after which an excess of diazomethane is added. When the reaction is completed the solvent is evaporated. The recrystallization is performed from petrol ether. The yield is almost quantitative and the product has m.p. 121–3°C.

¹H-NMR-spectrum (CDCl₃): δ 1.28 (1H, s), 2.73 (2H, t), 3.57 (2H, t), 3.65 (3H, s), 6.53 (2H, d), 6.80 (2H, d), 7.15, (5H, s), 7.29 (5H, s).

MS: m/z 330 (M⁺, 79), 299 (100), 221 (46), 191 (70), 121 (46), 91 (60).

(E)-isomer: the product is prepared from (E)-1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol (see Example 13a) in the same manner as the corresponding (Z)-isomer. The m.p. is 107–10°C.

¹H-NMR-spectrum (CDCl₃): δ 1.31 (1H, s), 2.80 (2H, t), 3.61 (2H, t), 3.81 (3H, s), 6.80–7.35 (14H, m).

(Z,E)-isomer mixture: The reaction is performed under dry conditions. First 34.8 g of 1,2-diphenyl-1-(4-methoxyphenyl)butane-1,4-diol are dissolved in 200 ml of acetic acid anhydride. Then 30 ml of acetyl chloride are added. The mixture is kept for 2 h at 100°C, after which the solvent is evaporated. (The intermediate is pure (Z,E)-4-acetoxy-1,2-diphenyl-1-(4-methoxyphenyl)-1-butene.) Then 200 ml of 94%

ethanol, 20 ml of water and 45 ml of 20% sodium hydroxide solution are added to the evaporation residue. The mixture is refluxed for 1 h. The solution is neutralized with 2 M hydrochloric acid, after which the ethanol is evaporated. Water is added to the residue and the product is extracted in ethyl acetate. The ethyl acetate solution is dried over sodium sulfate and the solvent is evaporated. The yield of the pure mixture of the isomers (Z:E 7:3), m.p. 91—105°C, is quantitative. The evaporation residue is recrystallized from a mixture of hexane and ethanol (95:5), and 14.5 g (44%) of (Z)-isomer are obtained.

b) 4-bromo-1,2-diphenyl-1-(4-methoxyphenyl)-1-butene (Z)

33.0 g of (Z)-1,2-diphenyl-1-(4-methoxyphenyl)-1-buten-4-ol are dissolved in 500 ml of dry acetonitrile. Then 39.3 g of triphenylphosphine and 49.8 g of carbon tetrabromide are added while stirring. The stirring is continued for 1 h at room temperature. The solvent is evaporated and the evaporation residue is dissolved in hot petrol ether. The insoluble material is removed by filtration. The mother liquor is evaporated, and the evaporation residue is recrystallized from methanol. The yield of the product is 26.7 g (68%) having m.p. 116—8°C.

¹H-NMR-spectrum (CDCl₃): δ 3.01 (2H, t), 3.28 (2H, t), 3.67 (3H, s), 6.54 (2H, d), 6.80 (2H, d), 7.17 (5H, s), 7.32 (5H, s).

MS: m/z 392/394 (M⁺, 86), 299 (65), 221 (79), 191 (94), 121 (100), 91 (50).

Example 7

1,2-diphenyl-1-(4-benzyloxyphenyl)butane-1,4-diol (RR,SS; RS,SR)

The (RR,SS; RS,SR)-isomer mixture is prepared from 13.2 g of cinnamaldehyde and 28.8 g of 4-benzyloxybenzophenone according to the procedure described in Example 9. Recrystallization is performed from toluene. The yield is 32.5 g (77%) of a product having m.p. 109—15°C. The product contains both isomer pairs (RR,SS; RS,SR 1:1).

¹H-NMR-spectrum (CD₃OD): δ 1.88—2.24 (2H, m), ~3.3 (2H, t), 3.85 (1H, t), 4.76 (2H, s), 4.91 (1H, s), 5.07 (1H, s), 6.62 (1H, d), 6.86—7.49 (16H, m), 7.57 (1H, d), 7.65 (1H, dd).

Example 8

a) 1,2-diphenyl-1-(4-benzyloxyphenyl)-1-buten-4-ol (Z and E)

The (Z, E)-isomer mixture is prepared from 42.4 g of 1,2-diphenyl-1-(4-benzyloxyphenyl)butane-1,4-diol (RR, SS:RS, SR 1:1) according to the procedure described in Example 6a. (The intermediate is pure (Z, E)-acetoxy-1,2-diphenyl-1-(4-benzyloxyphenyl)-1-butene (Z:E, 7:3)).

Isolation of the (Z)-isomer:

After the hydrolysis stage, the precipitate formed is collected by filtration. The precipitate is recrystallized from toluene-petrol ether (1:1), and 15.1 g (37%) of the (Z)-isomer is obtained, m.p. 141—3°C.

¹H-NMR-spectrum (CDCl₃): δ 1.30 (1H, s), 2.73 (2H, t), 3.57 (2H, t), 4.90 (2H, s), 6.60 (2H, d), 6.81 (2H, d), 7.15 (5H, s), 7.30 (5H, s), 7.31 (5H, s).

MS: (m/z 406 (M⁺, 28), 91 (100).

Isolation of the (E)-isomer:

After filtration of the hydrolysis solution another precipitate is formed, which is also collected by filtration. Recrystallization of the precipitate from toluene-petrol ether (1:4) gives 2.0 g (5%) of the (E)-isomer, m.p. 96—8°C.

¹H-NMR-spectrum (CDCl₃): δ 1.30 (1H, s), 2.79 (2H, t), 3.59 (2H, t), 5.05 (2H, s), 6.84—7.47 (19H, m).

MS: m/z 406 (M⁺, 5), 91 (100).

b) 4-chloro-1,2-diphenyl-1-(4-benzyloxyphenyl)-1-butene (Z and E).

(Z)-isomer: 40.6 g of (Z)-1,2-diphenyl-1-(4-benzyloxyphenyl)-1-buten-4-ol are dissolved in 400 ml of dry acetonitrile. Then 32.8 g of triphenylphosphine and 76.9 g of carbontetrachloride are added. The mixture is refluxed 1 h. On cooling, the product precipitates and is filtered off and recrystallized from ethanol. The yield is 39.5 g (93%) of a product having m.p. 115—6°C/128—9°C.

¹H-NMR-spectrum (CDCl₃): δ 2.91 (2H, t), 3.41 (2H, t), 4.91 (2H, s), 6.60 (2H, d), 6.81 (2H, d), 7.16 (5H, s), 7.32 (10H, s).

MS: m/z 424/426 (M⁺, 7/4), 91 (100).

(E)-isomer: The (E)-isomer is prepared in the same manner as the (Z)-isomer above. The product is recrystallized from methanol. The yield is 35.2 g (83%) of a product m.p. 91—3°C.

¹H-NMR-spectrum (CDCl₃): δ 2.97 (2H, t), 3.43 (2H, t), 5.06 (2H, s), 6.83—7.48 (19H, m).

Example 9

a) 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butane-1,4-diol (RR, SS and RS, SR).

The reaction is performed under dry conditions. 2.1 g of lithium aluminium hydride and 50 ml of dry tetrahydrofuran are placed in a flask. The 13.2 g of cinnamaldehyde in 50 ml of dry tetrahydrofuran are added while stirring and keeping the temperature at 25—35°C. The stirring is continued for another 30 min at room temperature. Then 26.9 g of 4-[2-(N,N-dimethylamino)ethoxy]benzophenone in 70 ml of dry

tetrahydrofuran are added while stirring.

0 095 875

The temperature is kept at 35–45°C during the addition. After stirring for 2 h at 40°C the reaction mixture is poured into 150 ml of 25% ammonium chloride solution, and aluminium hydroxide is precipitated and filtered off.

The filtrate is transferred to a separating funnel and the organic layer is separated. The aqueous layer is once again extracted with 60 ml of ethyl acetate. The organic layers are combined and dried over sodium sulfate. The solvent is evaporated. The residue is recrystallized from toluene. The yield is 27.5 g (68%). The product contains both (RR, SS)- and (RS, SR)-isomer pairs, the (RR, SS)-pair being enriched because of differences in solubility.

Isolation of the (RR, SS)-isomers:

Recrystallizing the product above from acetone gives 13.8 g (34%) of the (RR, SS)-isomer pair, m.p. 165–7°C (from toluene).

¹H-NMR-spectrum (CD₃OD): δ 2.07 (2H, q), 2.33 (6H, s), 2.76 (2H, t), 3.34 (2H, t), 3.86 (1H, dd), 4.10 (2H, t), 4.76 (2H, s), 6.80–7.25 (12H, m), 7.58 (2H, d).

Isolation of the (RS, SR)-isomers:

The acetone mother liquor above is evaporated. Recrystallizing the residue twice from acetone gives 5.3 g (13%) of the (RS, SR)-isomer pair, m.p. 139–41°C (from toluene).

¹H-NMR-spectrum (CD₃OD): δ 2.03 (2H, q), 2.27 (6H, s), 2.64 (2H, t), 3.32 (2H, t), 3.86 (1H, t), 3.93 (2H, t), 4.76 (2H, s), 6.56 (2H, d), 6.95–7.45 (10H, m), 7.66 (2H, dd).

b) 2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]tetrahydrofuran (RR, SS).

The compound is prepared from 40.5 g of (RR, SS)-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butane-1,4-diol in the same manner as 2,2,3-triphenyltetrahydrofuran in Example 2 except that 15 ml of concentrated sulfuric acid is used instead of 10 ml. Recrystallization is performed from ethanol. The yield of the product is 29.8 g (77%) having m.p. 83–5°C.

¹H-NMR-spectrum (CDCl₃): δ 1.90–2.50 (2H, m), 2.30 (6H, s), 2.68 (2H, t), 4.02 (2H, t), 3.85–4.50 (3H, m), 6.87 (2H, d), 7.02 (10H, s), 7.51 (2H, d).

MS: m/z 387 (M⁺, 2%), 269 (5%), 117 (22), 91 (7), 72 (10), 58 (100).

Example 10

a) 4-acetoxy-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene (Z, E).

The reaction is performed under dry conditions. 40.5 g of either (RR, SS)- or (RS, SR)-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butane-1,4-diol and 150 ml of acetic acid anhydride are placed in a flask. The temperature is raised to 90°C, where it is kept until the primary OH-group is completely acetylated. [4-acetoxy-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butan-1-ol is obtained as intermediate; m.p. of the (RR, SS)-isomer pair is 97–9°C]. While stirring the reaction mixture, 30 ml of acetyl chloride in 50 ml of acetic acid anhydride are added at 90°C. The stirring is continued at this temperature for 2 h. The solvent is evaporated. Then 1M sodium carbonate solution is added in excess, after which the product is extracted in toluene. The solution is dried over sodium sulfate, and the solvent is evaporated. The yield of the pure isomer mixture (Z:E 2:1) is quantitative. The m.p. of the (Z)-isomer is 67–9°C prepared from the corresponding (Z)-alcohol by refluxing in acetic acid.

b) 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol (Z and E).

Route 1: The compound is prepared from 44.7 g of (Z, E) 4-acetoxy-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene (Z:E 2:1) in the same manner as 1,1,2-triphenyl-1-buten-4-ol in Example 3b. The yield of the pure mixture of the isomers (Z:E 2:1), m.p. 93–100°C, is quantitative.

Route 2: Either 40.5 g of 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butane-1,4-diol or 38.7 g of 2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]tetrahydrofuran (either RR, SS) or (RS, SR)-isomer pair) are dissolved in 250 ml of dry ethanol containing an excess of hydrogen chloride gas. The mixture is refluxed for 1 h and the solvent is then evaporated. A mixture of the (Z)- and (E)-isomers as hydrochloride salts is obtained. The base can be liberated from the salt, for example in the following way. The evaporation residue is suspended in 1M sodium carbonate solution, after which the free base is extracted in ethyl acetate. The ethyl acetate solution is dried over sodium sulfate and the solvent is evaporated. The yield of the mixture of the isomers (Z:E 2:1) is quantitative, but the mixture contains as impurity about 5% of 2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]tetrahydrofuran.

Route 3: Either 40.5 g of 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butane-1,4-diol or 38.7 g of 2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]tetrahydrofuran (either (RR, SS)- or (RS, SR)-isomers) are dissolved in 250 ml of hot concentrated hydrochloric acid. The mixture is stirred for 15 min at 90–100°C. The cooled mixture is neutralized with 48% sodium hydroxide solution, after which the product is extracted in ethyl acetate. Then the ethyl acetate solution is dried over sodium sulfate and the solvent is evaporated. The yield of the mixture of isomers (Z:E 1:2) is quantitative, but the mixture contains as impurity about 5% of 2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]tetrahydrofuran.

Isolation of the (Z)-isomer as a free base: The mixture of the isomers (Z:E 2:1) from route 1) is recrystallized from toluene, and 15.9 g (41%) of the (Z)-isomer is obtained, m.p. 110–2°C.

¹H-NMR-spectrum (CDCl₃): δ 2.23 (6H, s), 2.60 (2H, t), 2.71 (2H, t), 3.53 (2H, t), 3.89 (2H, t), 6.53 (2H, d), 6.78 (2H, d), 7.12 (5H, s), 7.28 (5H, s).

Isolation of the (Z)-isomer as the hydrochloride salt: The mixture of the isomers (Z:E 2:1) from Route 1 is dissolved in ethanol and an excess of concentrated hydrochloric acid is added. The solvent is evaporated, and the residue is recrystallized twice from ethanol. 12.3 g (29%) of (Z)-isomer as the hydrochloride salt is obtained, m.p. 166–8°C (from acetone). The hydrochloride salt of the (Z)-isomer can also be prepared from the (Z)-isomer base for example in the following way. The (Z)-isomer is dissolved in ethanol. Then hydrogen chloride gas is passed into the solution. Finally the solvent is evaporated.

Isolation of the (E)-isomer: The mother liquors obtained in the isolation of the hydrochloride salt of the (Z)-isomer are combined and the solvent is evaporated. The evaporation residue is recrystallized from acetone, and 9.7 g (23%) of the hydrochloride salt of the (E)-isomer are obtained, m.p. 235–7°C. The (E)-isomer can be liberated from the salt by the same method as with the mixture of isomers. The m.p. of the (E)-isomer as a free base is 129–31°C (from toluene).

¹H-NMR-spectrum (CDCl₃): δ 2.31 (6H, s), 2.71 (2H, t), 2.78 (2H, t), 3.57 (2H, t), 4.05 (2H, t), 6.87 (2H, d), 6.94 (5H, s), 7.10 (5H, s), 7.21 (2H, d).

c) 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene (Z and E).

(Z)-isomer: The reaction is performed under dry conditions. 42.4 g of (Z)-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol are dissolved in 250 ml of chloroform. Then 23.8 g of thionyl chloride are added dropwise. The mixture is refluxed 3 h. The solvent is evaporated, after which the product is recrystallized from ethyl acetate. The yield of the hydrochloride salt is 36.7 g (83%), m.p. 194–6°C. The base can be liberated from the salt with 1M sodium carbonate solution, after which the base is extracted in toluene. The toluene solution is dried and the solvent is evaporated. The free base has m.p. 108–10°C (from acetone).

¹H-NMR-spectrum (CDCl₃): δ 2.27 (6H, s), 2.63 (2H, t), 2.91 (2H, t), 3.41 (2H, t), 3.92 (2H, t), 6.54 (2H, d), 6.79 (2H, d), 7.15 (5H, s), 7.31 (5H, s).

MS: m/z 405/407 (M⁺, 7/3), 72 (20), 58 (100).

The citric acid salt can be prepared as follows: 40.6 g of the (Z)-isomer as a free base are dissolved in 175 ml of warm acetone and 24.3 g of citric acid are dissolved in 100 ml of warm acetone. The solutions are combined and the mixture is allowed to cool. The citrate, m.p. 160–162°C, is collected by filtration.

(E)-isomer: The compound is prepared from (E)-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol in the same manner as the corresponding (Z)-isomer. The hydrochloride salt is crystallized from toluene. The yield is 35.8 g (81%) of a product having m.p. 183–5°C. The base can be liberated from the salt in the same manner as the corresponding (Z)-isomer. It has m.p. 69–71°C (from hexane).

¹H-NMR-spectrum (CDCl₃): δ 2.34 (6H, s), 2.74 (2H, t), 2.97 (2H, t), 3.43 (2H, t), 4.08 (2H, t), 6.80–7.30 (14H, m).

MS: m/z 405/407 (M⁺, 7/3), 72 (19), 58 (100).

Example 11

a) 4-benzyloxy-1,2-diphenylbutan-1-one.

This compound is prepared from 19.6 g of desoxybenzoin and 21.5 g of benzylether-protected bromoethanol according to the procedure described in Example 1(a).

b) 4-benzyloxy-1,2-diphenyl-1-[4-[(tetrahydropyran-2-yl)oxy]phenyl]butan-1-ol (RR, SS).

The compound is prepared from the evaporation residue obtained in step (a) and 38.6 g of tetrahydropyran-2-yl ether-protected 4-bromophenol according to the procedure described in Example 1(b).

c) 4-benzyloxy-1,2-diphenyl-1-(4-hydroxyphenyl)butan-1-ol (RR, SS).

The compound is prepared from the evaporation residue obtained in step b) according to the procedure described in Example 1(c).

d) 1,2-diphenyl-1-(4-hydroxyphenyl)-butane-1,4-diol (RR, SS).

The evaporation residue obtained in step c) is dissolved in 300 ml of 94% ethanol. Then 2 g of 5% palladium-on-charcoal are added. The reaction mixture is stirred at room temperature under a hydrogen atmosphere until one equivalent of hydrogen is consumed. The catalyst is filtered off. The solvent is evaporated, and the residue is crystallized from toluene. The yield is 12.7 g (38% from desoxybenzoin) of a product having m.p. 192–4°C.

¹H-NMR-spectrum (CD₃OD): δ 2.08 (2H, q), 3.34 (2H, t), 3.83 (1H, dd), 4.76 (3H, s), 6.76 (2H, d), 6.85–7.25 (10H, m), 7.47 (2H, d).

Example 12

2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydrofuran (RR, SS and RS, SR).

The (RR, SS)-isomers are prepared from 33.4 g of (RR, SS)-1,2-diphenyl-1-(4-hydroxyphenyl)butane-1,4-diol according to the procedure described in Example 2. Ethyl acetate is used as solvent in the extraction stage. The product is recrystallized from isopropanol. The yield after drying is 28.1 g (89%) of a product having m.p. 137–40°C.

¹H-NMR-spectrum (CD₃OD): δ 1.85—2.60 (2H, m), 3.80—4.45 (3H, m), 4.79 (1H, s), 6.75 (2H, d), 7.01 (10H, s), 7.44 (2H, d).

MS: 316 (M⁺, 6), 121 (25), 118 (100), 117 (52).

The (RS, SR)-isomers: The solvent of the isopropanol mother liquor above is evaporated. The evaporation residue is recrystallized from toluene, after which (RS, SR)-isomers, m.p. 119—132°C, are obtained in low yield.

¹H-NMR-spectrum (CD₃OD): δ 1.85—2.50 (2H, m), 3.75—4.45 (3H, m), 4.75 (1H, s), 6.41 (2H, d), 6.80—7.45 (10H, m), 7.62 (12H, dd).

Example 13

a) 1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol (Z and E).

Route 1: 31.6 g of 2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydrofuran are dissolved in 125 ml of acetic acid, after which 25 ml of 40% hydrogenbromide in acetic acid are added. The mixture is stirred for 1 h at 75°C. The solvent is evaporated. [The intermediate is the 4-acetoxy-1-butene derivative]. The evaporation residue is dissolved in a mixture containing 200 ml of 94% ethanol, 20 ml of water and 60 ml of 20% sodium hydroxide solution. Then the mixture is refluxed for 1 h. The solution is neutralized with 2M hydrochloric acid after which the ethanol is evaporated. Water is added to the residue and the product is extracted in ethyl acetate. The ethyl acetate solution is dried over sodium sulfate and the solvent is evaporated. The evaporation residue is treated with charcoal in methanol.

The methanol is evaporated and the product crystallized from toluene. The yield of the pure mixture of the isomers (Z:E 1:1), m.p. 164—7°C, is 22.8 g (72%).

Route 2: 33.0 g of 2,3-diphenyl-2-(4-methoxyphenyl)tetrahydrofuran are dissolved in 100 ml of acetic acid after which 50 ml of 40% hydrogenbromide in acetic acid are added. The mixture is refluxed for 2 h. Then 50 ml of 40% hydrogenbromide in acetic acid are added and the refluxing is continued for another 2 h. The solvent is evaporated. (The intermediate is the 4-acetoxy-1-butene derivative). The hydrolysis of the ester and the purification is performed according to the method in Route 1 above. The yield of the pure mixture of the isomers (Z:E 1:1) is 11.7 g (37%).

Isolation of the (E)-isomer: 20.0 g of the mixture of the isomers are dissolved in warm methylene chloride, and then an excess of 2M sodium hydroxide solution is added. After thorough mixing, the mixture is filtered. The precipitate, which is the (E)-isomer as a sodium salt, is suspended in 2M hydrochloric acid. The (E)-isomer is then extracted as the free phenol in ethyl acetate. The ethyl acetate solution is dried over sodium sulfate and the solvent is evaporated.

Finally the (E)-isomer is recrystallized from water-methanol (50:50). The yield is 7.2 g (36%) of a product having m.p. 165—7°C.

¹H-NMR-spectrum (CD₃COCD₃): δ 2.78 (2H, t), 3.54 (2H, t), 6.83 (2H, d), 6.90—7.35 (12H, m), 8.32 (1H, s).

MS: m/z 316 (M⁺, 64), 285 (100), 207 (87), 191 (58), 107 (55), 91 (94).

The sodium salt can be prepared as described above. Another method comprises dissolving the pure (E)-isomer in ethanol, adding an equivalent amount of sodium hydroxide in ethanol and evaporating the solvent. Finally the sodium salt is washed with acetone. It has m.p. 216—26°C.

Isolation of the (Z)-isomer: The sodium hydroxidemethylene chloride mother liquor is transferred to a separating funnel. The methylene chloride layer is removed. The water layer is neutralized with concentrated hydrochloric acid and then extracted with ethyl acetate. The ethyl acetate solution is dried over sodium sulfate and the solvent is evaporated. Finally (Z)-isomer is recrystallized from water-methanol (50:50). The yield is 6.2 g (31%) of a product having m.p. 169—71°C.

¹H-NMR-spectrum (CD₃COCD₃): δ 2.70 (2H, t), 3.52 (2H, t), 6.48 (2H, d), 6.74 (2H, d), 7.15 (5H, s), 7.32 (5H, s), 8.08 (1H, s).

MS: m/z 316 (M⁺, 35), 285 (38), 207 (54), 191 (37), 107 (50), 91 (100).

The sodium salt of the (Z)-isomer is prepared as described for the (E)-isomer. It has m.p. 205—217°C.

b) 4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)-1-butene (Z and E).

(Z)-isomer: 42.5 g of (Z)-4-chloro-1,2-diphenyl-1-(4-benzyloxyphenyl)-1-butene are dissolved in 800 ml of the mixture of ethyl acetate and ethanol (1:1). Then 4 g of 5% palladium-on-charcoal are added. The reaction mixture is stirred at room temperature under a hydrogen atmosphere until one equivalent of hydrogen is consumed. The catalyst is filtered off. The solvent is evaporated, and the product is washed with petrol ether. The yield is quantitative and the product has m.p. 85—7°C (from methanol).

¹H-NMR-spectrum (CD₃OD): δ 2.87 (2H, t), 3.38 (2H, t), 4.76 (1H, s), 6.42 (2H, d), 6.70 (2H, d), 7.15 (5H, s), 7.30 (5H, s).

MS: m/z 334/336 (M⁺, 94/32, 285 (71), 207 (78), 191 (56), 183 (100), 107 (55), 91 (86).

(E)-isomer: The (E)-isomer is prepared in the same manner as (Z)-isomer above. The product is washed with petrol ether. The yield is nearly quantitative, m.p. 109—12°C.

¹H-NMR-spectrum (CD₃OD): δ 2.96 (2H, t), 3.42 (2H, t), 4.79 (1H, s), 6.79 (2H, d), 6.93 (5H, s), 7.12 (2H, d), 7.12 (5H, s).

Example 14

4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)butane (RR, SS and RS, SR).

(RR, SS)-isomers are prepared from 42.5 g of (Z)-4-chloro-1,2-diphenyl-1-(4-benzyloxyphenyl)-1-butene according to the procedure described in Example 13 (b) except that 10% palladium-on-charcoal and 800 ml ethanol as solvent are used. The reaction is stopped when two equivalents of hydrogen have been consumed. After evaporation of the solvent the product is washed with petrol ether and recrystallized from methanol. It melts at 118—20°C.

¹H-NMR-spectrum (CDCl₃): δ 1.62—2.37 (2H, m), 2.94—3.43 (2H, m), 3.66 (1H, td), 4.08 (1H, d), 4.64 (1H, s), 6.77 (2H, d), 7.03 (5H, s), 7.12 (5H, s), 7.28 (2H, d).

MS: m/z 336/338 (M⁺, 1/0.4), 183 (100), 165 (13), 91 (14).

The benzoate is prepared from the (RR, SS)-isomers as follows. 0.4 g TBAH is dissolved in 5 ml of water. Then 3 ml of 20% sodium hydroxide solution and 3.4 g of the (RR, SS)-isomers are added. The mixture is stirred 10 min at room temperature. After that 1.7 g of benzoylchloride in 30 ml of chloroform is added. The mixture is stirred 2 h at room temperature.

Methylene chloride is added. After shaking, the water layer is removed and the organic layer is washed with water. The organic solution is dried over sodium sulfate and the solvent is evaporated. The evaporation residue is washed with methanol. The yield is quantitative of a product having m.p. 202—5°C.

The (RS, SR)-isomers are prepared from corresponding (E)-isomer in the same manner as the (RR, SS)-isomers above. The product is recrystallized from petrol ether. The yield is 62% of a product having m.p. 133—6°C.

¹H-NMR-spectrum (CDCl₃): δ 1.78—2.21 (2H, m), 2.94—3.44 (2H, m), 3.69 (1H, td), 4.08 (1H, d), 4.48 (1H, br s), 6.48 (2H, d), 6.96 (2H, d), 7.14 (5H, s), 7.33 (5H, br s).

The benzoate is prepared from the (RS, SR)-isomer as above and recrystallized from methanol. The yield is 88% of a product having m.p. 128—31°C.

Example 15

a) 4-[(tetrahydropyran-2-yl)oxy]-1,2-bis[[4-(tetrahydropyran-2-yl)oxy]phenyl]butan-1-one.

The compound is prepared from 39.6 g of 4,4'-bis[(tetrahydropyran-2-yl)oxy]desoxybenzoin and 20.9 g of tetrahydropyran-2-yl ether-protected bromoethanol according to the procedure described in Example 1(a).

b) 4-[(tetrahydropyran-2-yl)oxy]-1-phenyl-1,2-bis[[4-(tetrahydropyran-2-yl)oxy]phenyl]butan-1-ol (RS, SR).

The compound is prepared from the evaporation residue obtained in step (a) and 23.6 g of bromobenzene according to the procedure described in Example 1(b).

c) 1-phenyl-1,2-bis(4-hydroxyphenyl)butane-1,4-diol (RS, SR).

The compound is prepared from the evaporation residue obtained in step (b) according to the procedure described in Example 1 (c). The product is recrystallized from toluene. The yield is 8.4 g (24% from 4,4'-bis[(tetrahydropyran-2-yl)oxy]-desoxybenzoin) of a product having m.p. 213—5°C.

Example 16

2-phenyl-2,3-bis(4-hydroxyphenyl)tetrahydrofuran (RR, SS).

The compound is prepared from the evaporation residue obtained in Example 15(b) in the same way as 2,2,3-triphenyltetrahydrofuran in Example 2, except that the extraction is performed with ethyl acetate instead of toluene. The product is recrystallized from toluene. The yield is 14.9 g (45% from 4,4'-bis[(tetrahydropyran-2-yl)oxy]desoxybenzoin) of a product having m.p. 194—6°C.

¹H-NMR-spectrum (CD₃OD): δ 1.90—2.45 (2H, m), 3.80—4.45 (3H, m), 4.75 (2H, s), 6.48 (2H, d), 6.72 (2H, d), 6.83 (2H, d), 6.80—7.15 (5H, m), 7.41 (2H, d).

MS: m/z 332 (M⁺, 4), 134 (100).

Example 17

5-hydroxy-1,2-diphenylpentan-1-one.

Method 1: A mixture containing 19.6 g desoxybenzoin, 13.9 g of 3-bromopropan-1-ol, 1 g TBAH, 40 ml of 48% sodium hydroxide solution and 60 ml toluene is stirred for 24 h at 45°C. Water is added and the product extracted in toluene. The toluene solution is washed with water and dried over sodium sulfate. Finally the solvent is evaporated. The yield is nearly quantitative, but the product contains about 10—15% of the O-alkylation product. M.p. of the chromatographically purified sample is 45—8°C.

¹H-NMR-spectrum (CD₃OCD₃): δ 1.30—2.49 (4H, m), 2.82 (1H, s), 3.55 (2H, t), 4.82 (1H, t), 7.03—7.64 (8M, m), 8.04 (2H, dd).

Method 2: In the first stage 19.6 g of desoxybenzoin is alkylated with 15.8 g of 3-bromo-1-chloropropane according to the procedure described in method 1 except that the reaction is carried out at room temperature. Isolation gives an intermediate, 2,3-diphenyl-4,5-dihydro-6H-pyran in quantitative yield, but the product contains about 10% of noncyclic O-alkylation product. The m.p. of a sample which has been chromatographically purified and recrystallized from methanol is 119—22°C.

¹H-NMR-spectrum (CDCl₃): δ 1.87—2.17 (2H, m), 2.48 (2H, t), 4.16 (2H, dd), 7.02—7.55 (10H, m).

In the second stage the crude intermediate is first dissolved in 900 ml of ethanol. Then 100 ml of water and 5 ml of concentrated sulfuric acid are added. The mixture is stirred for 3 days at room temperature. The cyclic intermediate hydrolyses to 5-hydroxy-1,2-diphenylpentan-1-one. The reaction mixture is neutralized with 2M sodium hydroxide solution and the solvent is evaporated. The residue is extracted with toluene. The toluene solution is washed with water and dried over sodium sulfate. Then the solvent is evaporated. The evaporation residue is treated with hot petrol ether, which dissolves the noncyclic O-alkylation product from the first stage. After the mixture has cooled, the solvent is decanted to leave the pure product as an oil. The yield is 20.1 g (79%).

Example 18

1,1,2-triphenylpentane-1,5-diol.

The compound is prepared from 6.0 g of magnesium turnings in 42 ml of dry tetrahydrofuran, 39.3 g of bromobenzene in 84 ml of dry tetrahydrofuran and 25.4 g of 5-hydroxy-1,2-diphenylpentan-1-one in 75 ml of dry tetrahydrofuran according to the procedure described in Example 1(b). The product is recrystallized from toluene. The yield is 14.9 g (45%) of a product having m.p. 120–2°C.

¹H-NMR-spectrum (CD₃OD): δ 1.12–1.52 (2H, m), 1.75–2.12 (2H, m), 3.40 (2H, t), 3.71 (1H, t), 4.78 (2H, s), 6.90–7.44 (13H, m), 7.65 (2H, dd).

Example 19

a) 5-acetoxy-1,1,2-triphenyl-1-pentene.

The compound is prepared from 33.2 g of 1,1,2-triphenylpentane-1,5-diol according to the procedure described in Example 10a. The product is recrystallized from methanol. The yield is 22.1 g (62%) of a product having m.p. 80–1°C.

¹H-NMR-spectrum (CDCl₃): δ 1.49–1.89 (2H, m), 1.94 (3H, s), 2.44–2.62 (2H, m), 3.96 (2H, t), 6.95 (5H, br s), 7.12 (5H, s), 7.27 (5H, br s).

b) 1,1,2-triphenyl-1-penten-5-ol.

The compound is prepared from 35.6 g of 5-acetoxy-1,1,2-triphenyl-1-pentene according to the procedure described in Example 3b. The product is recrystallized from toluene-petrol ether. The yield is 12.6 g (40%) of a product having m.p. 128–30°C.

¹H-NMR-spectrum (CDCl₃): δ 1.30 (1H, s), 1.44–1.79 (2H, m), 2.44–2.63 (2H, m), 3.51 (2H, t), 6.96 (5H, br s), 7.13 (5H, s), 7.30 (5H, br s).

MS: m/z 314 (M⁺, 34), 268 (13), 205 (25), 191 (60), 167 (42), 105 (21), 91 (100).

Example 20

a) 5-[(tetrahydropyran-2-yl)oxy]-1,2-diphenylpentan-1-one.

The compound is prepared from 19.6 g of desoxybenzoin and 22.3 g of tetrahydropyran-2-yl ether-protected 3-bromopropanol according to the procedure described in Example 1(a).

b) 5-[(tetrahydropyran-2-yl)oxy]-1,2-diphenyl-1-[[4-(tetrahydropyran-2-yl)oxy]phenyl]pentan-1-ol (RR, SS).

The compound is prepared from the evaporation residue obtained in step (a) and 38.6 g of tetrahydropyran-2-yl ether-protected 4-bromophenol according to the procedure described in Example 1(b).

c) 1,2-diphenyl-1-(4-hydroxyphenyl)pentane-1,5-diol (RR, SS).

The compound is prepared from the evaporation residue obtained in step b) by the same method as 1,1,2-triphenylbutane-1,4-diol in Example 1(c).

The product is recrystallized from toluene. The yield is 11.1 g (32% from desoxybenzoin) of a product having m.p. 182–4°C.

¹H-NMR-spectrum (CD₃OD): δ 1.10–1.60 (2H, m), 1.65–2.15 (2H, m), 3.38 (2H, t), 3.61 (1H, dd), 4.80 (3H, s), 6.72 (2H, d), 6.80–7.25 (10H, m), 7.39 (2H, d).

Example 21

2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydropyran (RR, SS).

The compound is prepared from the evaporation residue obtained in Example 20 (b) by the same method as 2,2,3-triphenyltetrahydrofuran in Example 2. Ethyl acetate is used in the extraction. The evaporation residue is recrystallized from isopropanol to give the tetrahydropyran derivative. The yield is 7.3 g (22% from desoxybenzoin) of a product having m.p. 194–6°C.

¹H-NMR-spectrum (CD₃OD): δ 0.95–1.35 (1H, m), 1.55–2.60 (3H, m), 3.55–4.30 (3H, m), 4.80 (1H, s), 6.65–7.55 (14H, m).

MS: m/z 330 (M⁺, 13), 198 (38), 121 (57), 104 (100).

Example 22

a) 1,2-diphenyl-1-(4-hydroxyphenyl)-1-penten-5-ol (Z and E).

The isopropanol mother liquor obtained in Example 21 is evaporated. The evaporation residue is

recrystallized from toluene. A mixture of pentenol derivatives (Z:E) 1:1 is obtained. The yield is 5.6 g (17% from desoxybenzoin) of a product having m.p. 157—63°C.

The isomers are separated by the procedure described for their homologs in Example 13a.

The (E)-isomer is recrystallized from water-methanol (2:3). M.p. is 167—9°C.

¹H-NMR-spectrum (CD₃OD): δ 1.36—1.74 (2H, m), 2.44—2.67 (2H, m), 3.42 (2H, t), 4.75 (2H, s), 6.76 (2H, d), 6.91 (5H, br s), 7.05 (2H, d), 7.09 (5H, s).

MS: m/z 330 (M⁺, 100), 285 (39), 207 (73), 183 (89), 107 (57), 91 (90).

The (Z)-isomer is recrystallized from water-methanol (1:2). Its m.p. is 164—7°C.

¹H-NMR-spectrum (CD₃OD): δ 1.35—1.72 (2H, m), 2.37—2.57 (2H, m), 3.39 (2H, t), 4.74 (2H, s), 6.40 (2H, d), 6.68 (2H, d), 7.12 (5H, s), 7.26 (5H, br s).

MS: m/z 330 (M⁺, 100), 285 (19), 207 (70), 183 (97), 115 (76), 91 (81).

b) 5-acetoxy-1,2-diphenyl-1-(4-hydroxyphenyl)-1-pentene (Z, E).

The isomer mixture (Z:E 1:1) is prepared from the corresponding alcohol mixture (Z:E 1:1) by ester exchange reaction with ethyl acetate using concentrated hydrochloric acid as catalyst.

¹H-NMR-spectrum (CD₃OD): δ 1.34—1.69 (2H, m), 1.79 (1.5H, s), 1.83 (1.5H, s), 2.29—2.56 (2H, m), 3.79 (1H, t), 3.83 (1H, t), 4.67 (1H, s), 6.30 (1H, d), 6.59 (1H, d), 6.67 (1H, d), 6.94 (1H, d), 6.94 (1H, d), 6.81—7.24 (10H, m).

Example 23

5-chloro-1,2-diphenylpentan-1-one.

The compound is prepared from 19.6 g of desoxybenzoin, which is alkylated with 15.8 g of 3-bromo-1-chloropropane according to the procedure described in Example 17, method 1, except that the reaction time is only 15 min at room temperature. The product is recrystallized from methanol. The yield is 16.6 g (61%) of a product having m.p. 72—4°C.

¹H-NMR-spectrum (CDCl₃): δ 1.54—2.56 (4H, m), 3.50 (2H, t), 4.56 (1H, t), 7.21—7.50 (8H, m), 7.94 (2H, dd).

Example 24

a) 5-chloro-1,2-diphenyl-1-[[4-(tetrahydropyran-2-yl)oxy]phenyl]pentan-1-ol (RR, SS).

A Grignard complex is prepared under dry conditions by reacting 3.6 g of magnesium turnings in 50 ml of dry tetrahydrofuran with 38.6 g of tetrahydropyran-2-yl ether-protected 4-bromophenol in 75 ml of dry tetrahydrofuran. Then two thirds of the complex solution is added into a boiling mixture containing 27.3 g of 5-chloro-1,2-diphenylpentan-1-one and 100 ml of dry tetrahydrofuran. Then the complex solution is added portion-wise until all or nearly all the starting material has reacted, as shown by thin-layer chromatography of a sample of the reaction mixture. The reaction mixture is then refluxed for 1 h. The isolation is performed in the same manner as in Example 1(b).

b) 5-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)pentan-1-ol (RR, SS).

The compound is prepared from the evaporation residue obtained in step a) according to the procedure described in Example 1(c) except that only 5 g of concentrated sulfuric acid is used. A small sample is purified, by recrystallization from toluene-petrol ether, and then has m.p. 75—8°C.

¹H-NMR-spectrum (CD₃OD): δ 1.30—1.77 (2H, m), 1.85—2.15 (2H, m), 3.37 (2H, t), 3.64 (1H, dd), 4.60 (2H, s), 6.78 (2H, d), 6.88—7.22 (10H, m), 7.45 (2H, d).

Example 25

5-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)-1-pentene (Z).

The evaporation residue obtained in Example 24(b) is dissolved in 300 ml of ethanol, after which 10 ml of concentrated hydrochloric acid is added. The mixture is refluxed for 30 min. The solution is treated with charcoal, and filtered. The solvent is evaporated giving a mixture of the (Z)- and (E)-isomers. The isomer mixture is recrystallized from petrol ether to give 7.7 g (22% from 5-chloro-1,2-diphenylpentan-1-one) of the (Z)-isomer, m.p. 116—8°C.

¹H-NMR-spectrum (CD₃OD): δ 1.56—1.94 (2H, m), 2.47—2.66 (2H, m), 3.35 (2H, t), 4.74 (1H, s), 6.41 (2H, d), 6.69 (2H, d), 7.13 (5H, s), 7.22—7.41 (5H, m).

Example 26

4,4-diethoxy-1,2-diphenylbutan-1-one.

The compound is prepared from 19.6 g of desoxybenzoin and 19.7 g of bromoacetaldehyde diethyl acetal according to the procedure in Example 1(a). The reaction is performed however at 90°C and using TBAH (tetrabutylammonium hydrogen sulphate) as catalyst instead of TEBAC.

Example 27

a) 4,4-diethoxy-1,2-diphenyl-1-[4-(2-morpholinoethoxy)phenyl]butan-1-ol.

The compound is prepared from the evaporation residue obtained in Example 26 and 42.9 g of 1-bromo-4-(2-morpholinoethoxy)benzene according to the procedure described in Example 1(b).

b) 5-hydroxy-2,3-diphenyl-2-[4-(2-morpholinoethoxy)phenyl]tetrahydrofuran.

The evaporation residue obtained in step a) is dissolved in a mixture containing 19.5 g of concentrated sulfuric acid, 150 ml of water and 400 ml of tetrahydrofuran. The mixture is stirred for 3 h at room temperature. The solution is neutralized with 2M sodium hydroxide solution and the solvent is evaporated. The product is extracted in toluene containing ethyl acetate. The solution is dried over sodium sulfate. The solvent is evaporated, and the residue is recrystallized from toluene. The yield is 12.0 g (27% from desoxybenzoin) of a product having m.p. 150—3°C.

¹H-NMR-spectrum (CDCl₃): δ 2.20—2.55 (2H, m), 2.65 (4H, t), 2.86 (2H, t), 3.78 (4H, t), 4.14 (2H, t), 4.54 (1H, dd), 5.85—6.05 (1H, m), 6.80—7.30 (12H, m), 7.53 (2H, d).

Example 28

4-chloro-1,2-diphenyl-1-[4-[2-(N,N-diethylamino)ethoxy]phenyl]-1-butene (Z and E).

43.3 g of 1,2-diphenyl-1-[4-[2-(N,N-diethylamino)ethoxy]phenyl]butane-1,4-diol (pure enantiomer pairs or their mixture; m.p. of (RR, SS)-pair is 107—9°C) is suspended in 250 ml of toluene, after which 25 ml toluene is distilled off to dry the solution. The mixture is cooled to 0°C with stirring. While stirring and keeping the temperature at 0°C or a little below, 47.6 g of thionyl chloride of good quality are added. The mixture is stirred for 1 h at 0°C and the temperature is then allowed to rise to 22°C. The mixture is stirred at 80°C until the reaction is completed (about 3 h). After that, water is added to decompose the excess of thionyl chloride followed by 20% sodium hydroxide solution to liberate the product from its hydrochloride salt. The aqueous layer is discarded and the toluene layer is washed with water. Then the solvent is evaporated to leave a mixture of (Z)- and (E)-isomers (Z:E 7:3) as an oil in quantitative yield.

(Z)-isomer: The (Z)-isomer is isolated from the isomer mixture above as the hydrochloride salt because of the low melting point of the free base. The m.p. of the hydrochloride salt is 178—80°C. The (Z)-isomer may be freed from its salt by any normal method.

¹H-NMR-spectrum (CDCl₃): δ 1.01 (6H, t), 2.57 (4H, q), 2.77 (2H, t), 2.91 (2H, t), 3.41 (2H, t), 3.90 (2H, t), 6.53 (2H, d), 6.78 (2H, d), 7.15 (5H, s), 7.31 (5H, s).

(E)-isomer:

¹H-NMR-spectrum (CDCl₃): δ 1.07 (6H, t), 2.66 (4H, q), 2.89 (2H, t), 2.97 (2H, t), 3.42 (2H, t), 4.07 (2H, t), 6.90—7.20 (10H, m).

Example 29

1,2-diphenyl-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-1-buten-4-ol (Z and E).

A mixture containing 31.6 g of (Z,E)-1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol (Z:E 1:1), 25.5 g of 1-(2-chloroethyl)pyrrolidine hydrochloride, 48.3 g of anhydrous potassium carbonate and 500 ml of butanone is refluxed for 3 h, after which inorganic salts are removed by filtration. Then the solvent is evaporated and the evaporation residue is dissolved in a mixture of toluene and ethylacetate (2:1). After washing the organic solution with water and drying it with sodium sulfate, the solvent is evaporated leaving the products as an oil (Z:E 1:1).

(Z)-isomer: The evaporation residue above is transformed into its hydrochloride salt and treated with acetone. The (Z)-isomer hydrochloride salt is precipitated and collected by filtration. The base is liberated from its salt by conventional means and crystallised from toluene-petrol ether (1:1). In this way 15.3 g (37%) of the (Z)-isomer are obtained, m.p. 122—5°C.

¹H-NMR-spectrum (CDCl₃): δ 1.65—1.82 (4H, m), 2.55 (4H, t), 2.79 (2H, t), 3.56 (2H, t), 3.95 (2H, t), 6.53 (2H, d), 6.79 (2H, d), 7.14 (5H, s), 7.29 (5H, s).


(E)-isomer: It is isolated from acetone mother liquor above.

¹H-NMR-spectrum (CDCl₃): δ 1.70—1.89 (4H, m), 2.62 (4H, t), 2.79 (2H, t), 2.89 (2H, t), 3.58 (2H, t), 4.10 (2H, t), 6.80—7.15 (10H, m).

N-oxide of the (Z)-isomer: 4.13 g of the (Z)-isomer, 0.68 g of 50% H₂O₂ in water, and 40 ml of methanol are stirred for 42 h at room temperature. Water is then added and the precipitate filtered off. The N-oxide melts at 159—61°C.


Claims for the Contracting States: BE CH DE FR GB IT LI LU NL SE

1. A compound of the formula




(I)

OR



(II)

wherein n is 0 to 4, R_1 and R_2 , which can be the same or different, are H or OH; R_3 is H, OH, halogen, alkoxy of 1 to 4 carbon atoms, benzyloxy, methoxymethoxy, 2,3-dihydroxypropoxy or




wherein m is 1 or 2, R_6 and R_7 , which can be the same or different are H or an alkyl group of 1 to 4 carbon atoms, or



can form an N-containing three, four-, five- or six-membered heterocyclic ring; R_4 is OH, F, Cl, Br, I, mesyloxy, tosyloxy, formyloxy, alkylcarbonyloxy of 1 to 4 carbon atoms or CH_2R_4 is replaced by CHO; R_5 is H or OH; or R_4 and R_5 together form an —O— bridge between the carbon atoms to which they are attached, provided that


- when n is 0, then R_2 and R_3 are not both simultaneously hydrogen
- when n is 0, then R_3 must be other than halogen
- when n is 1 and R_4 and R_5 both are OH or together form an —O— bridge between the carbon atoms to which they are attached, then R_1 , R_2 and R_3 are not all simultaneously hydrogen
- when n is 2 and R_4 and R_5 together form an —O— bridge between the carbon atoms to which they are attached, then R_1 , R_2 and R_3 are not all simultaneously hydrogen and its non-toxic pharmaceutically acceptable salts, N-oxides and esters and mixtures thereof.

2. A compound according to claim 1 wherein n is 1 or 2, each of R_1 , R_2 and R_3 is hydrogen or hydroxy, at least one of R_1 , R_2 and R_3 being other than hydrogen, and R_3 may in addition be




where R_6 and R_7 are methyl or ethyl, R_4 is chlorine, bromine or hydroxy, and, in the case of formula II, R_5 is hydrogen or hydroxy, or R_4 and R_5 together form an O— bridge between the carbon atoms to which they are attached, and its non-toxic pharmaceutically acceptable salts and esters and mixtures thereof.

3. 1,2-diphenyl-1-(4-hydroxyphenyl)butane-1,4-diol, and its non-toxic pharmaceutically acceptable salts and esters.
4. 2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydrofuran, and its non-toxic pharmaceutically acceptable salts and esters.
5. 1,2-diphenyl-1-(4-methoxyphenyl)-1-buten-4-ol and its esters.
6. 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-buten-4-ol, and its non-toxic pharmaceutically acceptable salts and esters.
7. 2,3-diphenyl-2-(4-hydroxyphenyl)tetrahydropyran, and its non-toxic pharmaceutically acceptable salts and esters.
8. 1,2-diphenyl-1-(4-hydroxyphenyl)-1-penten-5-ol, and its non-toxic pharmaceutically acceptable salts and esters.
9. 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene and its non-toxic pharmaceutically acceptable salts.
10. 1-phenyl-1,2-bis(4-hydroxyphenyl)butane-1,4-diol, and its non-toxic pharmaceutically acceptable salts and esters.
11. 2-phenyl-2,3-bis(4-hydroxyphenyl)tetrahydrofuran, and its non-toxic pharmaceutically acceptable salts and esters.
12. 1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol, and its non-toxic pharmaceutically acceptable salts and esters.
13. 4-bromo-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene and its non-toxic pharmaceutically acceptable salts.
14. 4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)butane, and its non-toxic pharmaceutically acceptable salts and esters.
15. 4-chloro-1,2-diphenyl-1-(4-hydroxyphenyl)-1-butene, and its non-toxic pharmaceutically acceptable salts and esters.
16. 2,3-diphenyl-2-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]tetrahydrofuran and its non-toxic pharmaceutically acceptable salts, and its esters.
17. 1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]butane-1,4-diol and its non-toxic pharmaceutically acceptable salts, and its esters.
18. A compound as claimed in any of claims 1 to 17 and its non-toxic pharmaceutically acceptable salts and esters, for use in therapy in the treatment of hormone-dependent tumours.
19. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 17 or a non-toxic pharmaceutically acceptable salt or ester thereof and a compatible pharmaceutically acceptable carrier therefor.
20. Process for the preparation of a compound as claimed in claim 1 which comprises reacting a compound of the formula




- wherein n is as defined in claim 1, R'_1 is the same as R_1 as defined in claim 1 or is a hydroxyl group protected as a mixed acetal group, R'_4 is the same as R_4 as defined in claim 1 or is a protected hydroxyl group, and R_9 is a group R_2 or R_3 as defined in claim 1 or is a hydroxyl group protected as a mixed acetal group, with an organo-metallic compound of the formula:




- wherein M is $-\text{MgHal}$ or $-\text{Li}$ and R_{10} is a group R_2 or R_3 as defined in claim 1 or is a hydroxyl group protected as a mixed acetal group, to give a compound of the formula:






which is then treated, if necessary, to convert the radicals R'_1 , R'_4 , R_9 and R_{10} into the radicals R_1 , R_2 , R_3 and R_4 to provide a compound of formula II in which R_5 is hydroxyl, and optionally dehydrated the product to give a compound of formula I, or treating the product to provide a compound of formula II in which R_5 is hydrogen, or one in which R_4 and R_5 together form an $-\text{O}-$ bridge, and/or optionally treating the product to convert a radical R_1 , R_2 , R_3 , R_4 or R_5 into another such radical as defined in claim 1, and/or optionally treating the product to convert it into a non-toxic pharmaceutically acceptable salt, N-oxide or ester thereof.

21. A process for the preparation of a compound of formula (II) as claimed in claim 1 wherein R_4 and R_5 are OH, which comprises reacting an Al-complex of the formula



wherein R_1 is as defined in claim 1 and n_1 is 0 to 3 with a benzophenone derivative of the formula:




wherein R_2 and R_3 are as defined in claim 1.

22. A process according to claim 20 or 21 followed by the separation of the pure (Z)- and (E)-isomers of compound (I) from their mixtures as well as pure (RR, SS)- and (RS, SR)-enantiomer pairs of compound (II) from the corresponding mixtures, by fractional crystallization, fractional dissolution, chromatography or a combination thereof.




Claims for the Contracting State: AT


1. A process for the preparation of a compound of the general formula



or




wherein n is 0 to 4, R₁ and R₂, which can be the same or different are H or OH, R₃ is H, OH, halogen, alkoxy of 1 to 4 carbon atoms, benzyloxy, methoxymethoxy, 2,3-dihydroxypropoxy or




can form an N-containing three-, four-, five- or six-membered heterocyclic ring; R₄ is OH, F, Cl, Br, I, mesyloxy, tosyloxy, formyloxy, alkylcarbonyloxy of 1 to 4 carbon atoms or CH₂R₄ is replaced by CHO; R₅ is H or OH; or R₄ and R₅ together form an —O— bridge between the carbon atoms to which they are attached, provided that


- 50
- a) when n is 0, then R₂ and R₃ are not both simultaneously hydrogen
- b) when n is 0, then R₃ must be other than halogen
- c) when n is 1 and R₄ and R₅ both are OH or together form an —O— bridge between the carbon atoms to which they are attached, then R₁, R₂ and R₃ are not all simultaneously hydrogen
- 55 d) when n is 2 and R₄ and R₅ together form an —O— bridge between the carbon atoms to which they are attached, then R₁, R₂ and R₃ are not all simultaneously hydrogen and its non-toxic pharmaceutically acceptable salts N-oxides and esters which comprises reacting a compound of the formula:



wherein n is as hereinbefore defined, R'₁ is the same as R₁ as hereinbefore defined or is a hydroxyl group protected as a mixed acetal group, R'₄ is the same as R₄ as hereinbefore defined or is a protected hydroxyl group, and R₉ is a group R₂ or R₃ as hereinbefore defined or is a hydroxyl group protected as a mixed acetal group, with an organo-metallic compound of the formula:




wherein M is —MgHal or —Li and R₁₀ is a group R₂ or R₃ as hereinbefore defined or is a hydroxyl group protected as a mixed acetal group, to give a compound of the formula:



- which is then treated, if necessary, to convert the radicals R'₁, R'₄, R₉ and R₁₀ into the radicals R₁, R₂, R₃ and R₄ to provide a compound of formula II in which R₅ is hydroxyl, and optionally dehydrating the product to give a compound of formula I or treating the product to provide a compound of formula II in which R₅ is hydrogen, or one in which R₄ and R₅ together form an —O— bridge, and/or optionally treating the product to convert a radical R₁, R₂, R₃, R₄ or R₅ into another such radical as hereinbefore defined, and/or optionally treating the product to convert it into a non-toxic pharmaceutically acceptable salt, N-oxide or ester thereof.

2. A process according to claim 1 which comprises

- 1) reacting a compound of the formula




- wherein R₁ and R₂ are as defined in claim 1 or a mixed acetal group, n is as defined in claim 1 and OR₈ is a mixed acetal, benzyloxy or hydroxy, either by a Grignard reaction with a phenylmagnesiumhalide derivative of the formula



- or with a corresponding lithium compound of the formula




wherein R_3 is as defined in claim 1 or a mixed acetal group to give a protected or unprotected triphenyldiol of the formula




from which compound any protecting group R_8 and protecting group in a phenyl ring are removed, to give a compound of formula (II) wherein R_4 and R_5 are OH;


2) reacting a compound of the formula




wherein R_1 and R_3 are as defined in claim 1 or a mixed acetal, n is as defined in claim 1 and OR_8 is a mixed acetal, benzyloxy or hydroxy, either by a Grignard reaction with a phenylmagnesiumhalide derivative of the formula



or with a corresponding lithium compound of the formula



wherein R_2 is as defined in claim 1 or a mixed acetal to give a protected or unprotected triphenyldiol of the formula




from which compound any protecting group R_8 and protecting group in a phenyl ring are removed, to give a compound of formula (II) wherein R_4 and R_5 are OH;

3) dehydrating a compound of formula (II) wherein R_4 and R_5 both are OH, to give a compound of formula (II) wherein R_4 and R_5 together form an $-\text{O}-$ bridge between the carbon atoms to which they are attached;




4) dehydrating a compound of formula (II) wherein R_4 and R_5 are both OH, to give a compound of formula (II) wherein R_4 is OH;

5) removing the protecting group R_6 , which is other than hydrogen, and/or protecting group in a phenyl ring, and dehydrating a compound of the formula



20 wherein R_1 , R_2 and R_3 are as defined in claim 1 or mixed acetal, n is as defined in claim 1 and OR_8 is a mixed acetal, benzyloxy or hydroxy, to give a compound of formula (II) wherein R_4 and R_5 together form an —O— bridge between the carbon atoms to which they are attached;


6) removing the protecting group R_6 , which is other than hydrogen and/or a protecting group in a phenyl ring, and dehydrating a compound of the formula




40 wherein R_1 , R_2 , R_3 , n and OR_8 are as defined in step 5), to give a compound of formula (I) wherein R_4 is OH;

7) ring opening a compound of formula (II), wherein R_4 and R_5 together form an —O— bridge between the carbon atoms to which they are attached, to give a compound of formula (I) wherein R_4 is OH or halogen;

8) reacting an Al-complex of the formula



wherein R_1 is as defined in claim 1 and n_1 is 0 to 3, with a benzophenone derivative of the formula



wherein R_2 and R_3 are as defined in claim 1, to give a compound of formula (II) wherein R_4 and R_5 are OH;


9) esterifying a compound of formula (I) or (II) wherein R_4 is OH, with a carboxylic acid of 1 to 5 carbon atoms or with the corresponding carboxylic acid derivative, to give a compound of formula (I) or (II) wherein R_4 is formyloxy or alkylcarbonyloxy of 1 to 4 carbon atoms;

10) dehydrating a compound of formula (II) wherein R_5 is OH, to give a corresponding compound of formula (I);

11) hydrolysing a compound of formula (I), wherein R_4 is formyloxy or alkylcarbonyloxy of 1 to 4 carbon atoms, to give a compound of formula (I) wherein R_4 is OH;

12) reacting a compound of formula (II) wherein R_4 and R_5 are both OH or together form an —O— bridge between the carbon atoms to which they are attached, with an acid catalyst in a carboxylic acid containing 1 to 5 carbon atoms, to give a compound of formula (I) wherein R_4 is formyloxy or alkylcarbonyloxy of 1 to 4 carbon atoms;


13) reacting a compound of the formula




wherein R_1 , R_2 , R_3 , OR_8 and n are as defined in step 1) and 2), with an appropriate acid catalyst in a carboxylic acid containing 1 to 5 carbon atoms, to give a compound of formula (I) wherein R_4 is formyloxy or alkylcarbonyloxy of 1 to 4 carbon atoms;

14) dealkylating a compound of formula (I) or (II), wherein at least one of R_1 , R_2 and R_3 is alkoxy or aralkoxy, to give a compound of formula (I) or (II) wherein at least one of R_1 , R_2 and R_3 is OH;


15) alkylating a compound of formula (I) or (II) wherein R_3 is OH, with diazomethane or alkylhalide derivative of the formula



wherein R_{11} is an alkyl group of 1 to 4 carbon atoms, benzyl, methoxymethyl, 2,3-dihydroxypropyl or



wherein R_6 , R_7 and m are as defined in claim 1, to give a compound of formula (I) or (II) wherein R_3 is alkoxy of 1 to 4 carbon atoms, benzyloxy, methoxymethoxy, 2,3-dihydroxypropoxy or




wherein m , R_6 and R_7 are as defined in claim 1;


16) alkylating a compound of formula (I) wherein R_3 is OH, with a dihaloalkane of the formula



wherein m is as defined in claim 1 and the radicals hal are halogen atoms, which can be the same or different, to give a 4-(haloalkoxy)phenyldiphenylalkane of the formula:




wherein R_1 , R_2 , R_4 and n and m are as defined in claim 1 and hal is halogen, which is further reacted with an amine of the formula:




wherein R_6 and R_7 are as defined in claim 1, to give a compound of formula (I) wherein R_3 is aminoalkoxy as defined in claim 1;


17) alkylating a compound of formula (II), wherein R_3 is OH, with dihaloalkane of the formula:



wherein m is as defined in claim 1 and the radicals hal are halogen atoms, which can be the same or different, to give a 4-(haloalkoxy)phenyldiphenylalkane of the formula:



wherein R_1 , R_2 , R_4 , R_5 , n, m are as defined in claim 1 and hal is halogen, which is further reacted with an amine of the formula



wherein R_6 and R_7 are as defined above, to give a compound of formula (II) wherein R_3 is aminoalkoxy as defined in claim 1;

18) substituting the hydroxy group R_4 in a compound of formula (I) or (II) by halogen, to give the corresponding compound of formula (I) or (II) wherein R_4 is halogen;

19) reacting a compound of formula (I) or (II) wherein R_4 is OH, with methane sulfonic acid chloride or toluene sulfonic acid chloride, to give a compound of formula (I) or (II) wherein R_4 is mesyloxy or tosyloxy;

20) dehydrating and substituting the hydroxy group of a compound of formula (II), wherein R_4 and R_5 both are OH, to give a compound of formula (I) wherein R_4 is halogen;




0 095 875


21) treating a compound of formula (II), wherein R_4 and R_5 both are OH, with thionyl chloride, to give a compound of formula (I) wherein R_4 is Cl;

22) substituting a compound of formula (I) or (II), wherein R_4 is mesyloxy, tosyloxy or halogen, with halogen, to give a compound of formula (I) or (II) wherein R_4 is halogen;

23) reacting a compound of the formula:



wherein R_1 and R_2 are as defined in claim 1 or mixed acetal, n is as defined in claim 1 and hal is halogen, either by a Grignard reaction with a phenylmagnesiumhalide derivative or with the corresponding lithium compound as defined in step 1) to give a triphenylhydroxyhalide of the formula:




from which compound a possible protecting group in a phenyl ring is removed, to give a compound of formula (II) wherein R_4 is halogen and R_5 is hydroxy;

24) carrying out the same reactions as in step 23) except that the groups R_2 and R_3 of the starting material and the reagent are interchanged, to give a compound of formula (II) wherein R_4 is halogen and R_5 is hydroxy;

25) dehydrating and removing any protecting group in a phenyl ring of a compound of formula (II), wherein R_5 is OH and R_3 is as defined in step 23), to give a compound of formula (I) wherein R_3 is OH and R_4 is halogen;


26) converting a compound of the formula:




wherein R_1 , R_2 , R_3 and n are as defined in claim 1, Z is H, Y is H or OH or Z and Y together form a bond, and X is halogen to the corresponding Grignard-complex or lithium salt wherein X is Mghal or Li, respectively, and reacting this complex or salt with formaldehyde, ethylene oxide or trimethylene oxide, to give a compound of formula (I) or (II) wherein R_4 is OH and n is 1 to 4;

27) reacting a compound of formula (I) or (II) wherein n is 0 to 3 and R_4 is halogen, mesyloxy or tosyloxy, with a cyano group to give a triphenyl nitrile of the formula:






wherein R₁, R₂ and R₃ are as defined in claim 1, Z and Y as defined in step 26) and n is 0 to 3, hydrolysing this compound to the corresponding triphenylcarboxylic acid, and reducing the said carboxylic acid in one step or via an intermediate, to give a compound of formula (I) or (II) wherein R₄ is OH and n is 1 to 4;
28) converting a compound of the formula




as defined in step 26), wherein X is MgHal or Li, with carbon dioxide to give the corresponding triphenylcarboxylic acid, which is finally reduced, in one step or via an intermediate to give a compound of formula (I) or (II) wherein R₄ is OH and n is 1 to 4;


29) reacting a protected diphenyloxoaldehyde of the formula:



wherein R₁, R₂ and n are as defined in claim 1 or a mixed acetal, and R₁₃ and R₁₄, which can be the same or different, are alkyl groups or form together a 1,3-propylene group, with a compound of the formula




wherein R₃ is as defined in claim 1 or a mixed acetal and X is Mghal or Li, to give a protected triphenylhydroxyaldehyde of the formula:




and finally removing the protecting group, and also any protecting group in a phenyl ring, to give a compound of formula (II) wherein CH_2R_4 is replaced by CHO and R_5 is OH ;

30) carrying out the same reaction as in step 29) except that the groups R_2 and R_3 of the starting material and the reagent are interchanged, to give a compound of formula (II) wherein CH_2R_4 is replaced by CHO and R_5 is OH ;

31) dehydrating a compound of the formula:




or




or a mixture of said compounds wherein R_1 , R_2 , R_3 and n are as defined in claim 1, to give a compound of formula (I) wherein CH_2R_4 is replaced by CHO ;

32) dehydrating a protected triphenylaldehyde of the formula:



wherein R_1 , R_2 , R_3 , n , R_{13} and R_{14} are as defined in step 29), to give a compound of the formula:



and finally removing the protecting group from this compound, to give a compound of formula (I) wherein CH_2R_4 is replaced by CHO ;

33) oxidizing a compound (I) or (II) wherein R_4 is OH , to give a compound of formula (I) or (II) wherein CH_2R_4 is replaced by CHO ;

34) reducing a compound of formula (I) or (II), wherein R_4 is COOH , in a single step or via an intermediate, to give a compound of formula (I) or (II) wherein CH_2R_4 is replaced by CHO ;


35) hydrogenating a compound of formula (I) or a compound of formula (II) wherein R_5 is other than hydrogen, to give a compound of formula (II) wherein R_5 is H ; or

36) alkylating a compound of formula (I) or (II) wherein at least one of R_1 , R_2 and R_3 is OH , with a suitable alkylating agent, to give a compound of formula (I) or (II) wherein at least one of R_1 , R_2 and R_3 is alkoxy of 1 to 4 carbon atoms, benzyloxy, or methoxymethoxy.

3. A process according to claim 1 or 2, followed by the separation of the pure (Z)- and (E)-isomers of compound (I) from their mixtures as well as pure (RR, SS)- and (RS, SR)-enantiomer pairs of compound (II) from the corresponding mixtures, by fractional crystallization, fractional dissolution, chromatography or a combination thereof.


Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LI LU NL SE

1. Verbindung der allgemeinen Formel




(I)

bzw.




(II)

wobei n 0 bis 4 ist, R_1 und R_2 , die gleich oder verschieden sind, H bzw. OH darstellen, R_3 H , OH , ein Halogen, oder eine Alkoxy-Gruppe mit 1 bis 4 Kohlenstoffatomen, eine Benzyloxy-, Methoxymethoxy-, 2,3-dihydroxypropoxy-Gruppe oder die Gruppe



ist, wobei m 1 oder 2 ist, R_6 und R_7 , die gleich oder verschieden sind, H oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen, bzw.



einen N-haltigen heterozyklischen Ring mit drei, vier, fünf oder sechs Gliedern darstellt, R_4 OH , F , Cl , Br I , eine Mesyloxy, Tosyloxy, Formyloxy-, Alkylcarbonyloxy-Gruppe mit 1 bis 4 Kohlenstoffatomen ist bzw. CH_2R_4 durch CHO substituiert wird, R_5 H oder OH ist, bzw. R_4 und R_5 zusammen eine $-\text{O}-$ Brücke zwischen den Kohlenstoffatomen, an die sie angegliedert sind, bilden, vorausgesetzt, daß folgende Bedingungen erfüllt sind:

a) wenn $n = 0$, sind R_2 und R_3 nicht beide gleichzeitig Wasserstoff,




b) wenn $n = 0$, darf R_3 kein Halogen sein,

c) wenn $n = 1$ und R_4 und R_5 beide OH sind bzw. zusammen —O—Brücke zwischen den Kohlenstoffatomen bilden, an die sie sich angliedern, dann sind R_1 , R_2 und R_3 nicht alle gleichzeitig Wasserstoff,

d) wenn $n = 2$ und R_4 und R_5 zusammen eine —O—Brücke zwischen den Kohlenstoffatomen bilden, an die sie angegliedert sind, dann sind R_1 , R_2 und R_3 nicht alle gleichzeitig Wasserstoff, sowie ihre atoxischen, pharmazeutisch annehmbaren Salze, deren N-Oxide, Ester und Mischungen aus beiden.

2. Verbindung nach Anspruch 1, wobei n 1 oder 2 ist, R_1 , R_2 und R_3 jeweils Wasserstoff oder eine Hydroxylgruppe sind, wobei zumindest eine der Gruppen R_1 , R_2 und R_3 nicht Wasserstoff ist und R_3 zusätzlich



sein kann, während R_6 und R_7 eine Methyl- oder Äthyl-Gruppe darstellt, R_4 Chlor, Brom oder eine Hydroxylgruppe ist, und bei Formel II R_5 Wasserstoff oder eine Hydroxylgruppe ist, bzw. R_4 und R_5 zusammen eine —O—Brücke zwischen den Kohlenstoffatomen bilden, an die sie angegliedert ist, sowie deren atoxische, pharmazeutisch annehmbare Salze und Ester und deren Mischungen.

3. 1,2-Diphenyl-1-(4-hydroxyphenyl)butan-1,4-diol und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

4. 2,3-Diphenyl-2-(4-hydroxyphenyl)tetrahydrofuran und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

5. 1,2-Diphenyl-1-(4-methoxyphenyl)-1-buten-4-ol und dessen Ester.

6. 1,2-Diphenyl-1-[4-[2-(N,N-dimethylamino)äthoxyl]phenyl]-1-buten-4-ol und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

7. 2,3-Diphenyl-2-(4-hydroxyphenyl)tetrahydropyran und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

8. 1,2-Diphenyl-1-(4-hydroxyphenyl)-1-penten-5-ol und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

9. 4-Chlor-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)äthoxyl]phenyl]-1-buten und dessen atoxische, pharmazeutisch annehmbare Salze.

10. 1-Phenyl-1,2-bis(4-hydroxyphenyl)butan-1,4-diol und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

11. 2-Phenyl-2,3-bis(4-hydroxyphenyl)tetrahydrofuran und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

12. 1,2-Diphenyl-1-(4-hydroxyphenyl)-1-buten-4-ol, und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

13. 4-Brom-1,2-Diphenyl-1-[4-[2-(N,N-dimethylamino)äthoxyl]phenyl]-1-buten und dessen atoxische, pharmazeutisch annehmbare Salze.

14. 4-Chlor-1,2-diphenyl-1-(4-hydroxyphenyl)butan und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.

15. 4-Chlor-1,2-diphenyl-1-(4-hydroxyphenyl)-1-buten und dessen atoxische, pharmazeutisch annehmbare Salze und Ester.


16. 2,3-Diphenyl-2-[4-[2-(N,N-dimethylamino)äthoxyl]phenyl]tetrahydrofuran und dessen atoxische, pharmazeutisch annehmbare Salze.

17. 1,2-Diphenyl-1-[4-[2-(N,N-dimethylamino)äthoxyl]phenyl]butan-1,4-diol und dessen atoxische, pharmazeutisch annehmbare Salze und dessen Ester.


18. Verbindung nach einem der Ansprüche 1 bis 17 und deren atoxische, pharmazeutisch annehmbare Salze und Ester zur Verwendung in der therapeutischen Behandlung hormonabhängiger Tumore.

19. Pharmazeutische Mischung mit einer Verbindung nach einem der Ansprüche 1 bis 17 bzw. mit einem von deren atoxischen, pharmazeutisch annehmbaren Salzen oder Estern, und mit einem damit verträglichen, pharmazeutisch annehmbaren Träger für diese Mischung.


20. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, bei welchem eine Verbindung der allgemeinen Formel



wobei n den Festlegungen gemäß Anspruch 1 entspricht, R'_1 gleich R_1 gemäß Anspruch 1 oder eine als gemischte Acetalgruppe geschützte Hydroxylgruppe ist, R'_4 die gleiche Bedeutung wie R_4 in Anspruch 1 hat oder eine geschützte Hydroxylgruppe ist, und R_9 eine R_2 - oder R_3 -Gruppe gemäß Anspruch 1 oder eine als gemischte Acetalgruppe geschützte Hydroxylgruppe ist, mit einer metallorganischen Verbindung der allgemeinen Formel




zur Reaktion gebracht wird, wobei M -MgHal bzw. -Li ist und R_{10} eine R_2 - oder R_3 -Gruppe nach Anspruch 1 oder eine als gemischte Acetalgruppe geschützte Hydroxylgruppe ist, so daß die Verbindung folgende Struktur nach der allgemeinen Formel erhält:




welche anschließend, soweit erforderlich, zur Umsetzung der Radikale R'_1 , R'_4 , R_9 und R_{10} in die Radikale R_1 , R_2 , R_3 und R_4 behandelt wird, so daß eine Verbindung der allgemeinen Formel II entsteht, bei welcher R_5 eine Hydroxylgruppe ist, worauf bei Bedarf das Reaktionsprodukt dehydratisiert wird, sodaß eine Verbindung der allgemeinen Formel I entsteht, bzw. das Reaktionsprodukt so behandelt wird, daß eine Verbindung der allgemeinen Formel II entsteht, bei welcher R_5 Wasserstoff ist, bzw. eine Verbindung, bei der R_4 und R_5 zusammen eine -O-Brücke bilden, und/oder bei welchem das Reaktionsprodukt bei Bedarf so behandelt wird, daß ein Radikal R_1 , R_2 , R_3 , R_4 oder R_5 in ein anderes Radikal gemäß den Festlegungen nach Anspruch 1 umgesetzt wird, und/oder bei welchem bei Bedarf das Reaktionsprodukt so behandelt wird, daß es in ein atoxisches, pharmazeutisch annehmbares Salz, N-Oxid oder einen Ester übergeführt wird.

21. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel II gemäß Anspruch 1, wobei R_4 und R_5 OH-Gruppen sind, bei welchem ein Al-Komplex der allgemeinen Formel



wobei R_1 den Festlegungen gemäß Anspruch 1 entspricht und n_1 0 bis 3 mit einem Benzophenonderivat der allgemeinen Formel



(XV)




ist, wobei R_2 und R_3 den Festlegungen gemäß Anspruch 1 entsprechen, zur Reaktion eingesetzt wird.


22. Verfahren nach Anspruch 20 bzw. 21, mit anschließender Trennung der reinen (Z-) und (E)-Isomeren der Verbindung (I) aus deren Mischungen, sowie von Paaren reiner (RR,SS)- und (RS,SR)-Enantiomeren der Verbindung (II) aus den entsprechenden Mischungen durch Kristallisations-differentiation, fraktionierende Auflösung, auf chromatographischem Wege oder in einem daraus kombinierten Verfahren.

Patentansprüche für den Vertragsstaat: AT


1. Verfahren zur Herstellung einer Verbindung der allgemeinen Formel




bzw.



- wobei n 0 bis 4 ist, R_1 und R_2 , die gleich oder verschieden sind, H bzw. OH darstellen, R_3 H, OH, ein Halogen, oder eine Alkoxy-Gruppe mit 1 bis 4 Kohlenstoffatomen, eine Benzyloxy-, Methoxymethoxy-, 2,3-dihydroxypropoxy-Gruppe oder die Gruppe



ist, wobei m 1 oder 2 ist, R_6 und R_7 , die gleich oder verschieden sind, H oder eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen, bzw.




- sind, einen N-haltigen heterozyklischen Ring mit drei, vier, fünf oder sechs Gliedern darstellen können, R_4 OH, F, Cl, Br I, eine Mesyloxy-, Tosyloxy-, Formyloxy-, Alkylcarbonyloxy-Gruppe mit 1 bis 4 Kohlenstoffatomen ist bzw. CH_2R_4 durch CHO substituiert wird, R_5 H oder OH ist, bzw. R_4 und R_5 zusammen eine —O—Brücke zwischen den Kohlenstoffatomen, an die sie angeliedert sind, bilden, und deren atoxische, pharmazeutisch annehmbar Salze und Ester und Mischungen aus beiden, vorausgesetzt, daß folgende Bedingungen erfüllt sind:


- wenn $n = 0$, sind R_2 und R_3 nicht beide gleichzeitig Wasserstoff,
- wenn $n = 0$, darf R_3 kein Halogen sein,
- wenn $n = 1$ und R_4 und R_5 beide OH sind bzw. zusammen eine —O—Brücke zwischen den Kohlenstoffatomen bilden, an die sie sich angeliedern, dann sind R_1 , R_2 und R_3 nicht alle gleichzeitig Wasserstoff,




d) wenn $n = 2$ und R_4 und R_5 zusammen eine $-O-$ Brücke zwischen den Kohlenstoffatomen bilden, an die sie angegliedert sind, dann sind R_1 , R_2 und R_3 nicht alle gleichzeitig Wasserstoff, und von deren atoxischen, pharmazeutisch annehmbaren Salzen, N-Oxiden und Estern, wobei eine Verbindung der allgemeinen Formel



wobei n die vorstehend genannte Bedeutung hat, R'_1 die gleiche Bedeutung wie R_1 gemäß vorstehender Festlegung hat bzw. eine als gemischte Acetalgruppe geschützte Hydroxylgruppe ist, R'_4 die gleiche Bedeutung wie R_4 gemäß vorstehender Festlegung hat bzw. eine solche geschützte Gruppe darstellt, und R_9 eine Gruppe R_2 oder R_3 gemäß vorstehender Festlegung oder eine als gemischte Acetalgruppe geschützte Hydroxylgruppe ist, zur Reaktion gebracht wird mit einer metallorganischen Verbindung der allgemeinen Formel:




wobei $M - \text{MgHal}$ bzw. $-\text{Li}$ ist und R_{10} eine R_2 - bzw. R_3 -Gruppe gemäß vorstehender Festlegung oder eine als gemischte Acetalgruppe geschützte Hydroxylgruppe ist, so daß sich eine Verbindung der folgenden Formel ergibt:



die anschließend bei Bedarf zur Umsetzung der Radikale R'_1 , R'_4 , R_9 und R_{10} in die Radikale R_1 , R_2 , R_3 und R_4 behandelt wird, so daß eine Verbindung der allgemeinen Formel II entsteht, bei welcher R_5 eine Hydroxylgruppe ist, worauf, soweit erforderlich, das Reaktionsprodukt dehydratisiert wird, so daß eine Verbindung der allgemeinen Formel I entsteht, bzw. das Reaktionsprodukt so behandelt wird, daß eine Verbindung der allgemeinen Formel II entsteht, bei welcher R_5 Wasserstoff ist, oder eine Verbindung, bei welcher R_4 und R_5 zusammen eine $-O-$ Brücke bilden, und/oder wobei das Reaktionsprodukt bei Bedarf so behandelt wird, daß ein Radikal R_1 , R_2 , R_3 , R_4 oder R_5 in ein anderes der vorstehend definierten Radikale umgesetzt wird, und/oder daß es in eines seiner atoxischen, pharmazeutisch verträglichen Salze, N-Oxide oder Ester übergeführt wird.

2. Verfahren nach Anspruch 1, bei welchem

1) eine Verbindung der allgemeinen Formel



wobei R_1 und R_2 die Bedeutung gemäß Anspruch 1 haben bzw. eine gemischte Acetalgruppe darstellen, n der Festlegung aus Anspruch 1 entspricht OR_8 eine gemischte Acetalgruppe, Benzyloxy- oder Hydroxylgruppe ist, entweder in einer Grignard-Reaktion mit einem Phenyl-Magnesiumhalogenidderivat der allgemeinen Formel



oder einer entsprechenden Lithiumverbindung der allgemeinen Formel

5




reagiert wird, wobei R_3 den Festlegungen in Anspruch 1 entspricht oder eine gemischte Acetalgruppe ist, so daß sich ein geschütztes oder ungeschütztes Triphenyldiol der allgemeinen Formel

10

15

20




25 ergibt, aus welcher Verbindung jede schützende Gruppe R_8 und jede schützende Gruppe in einem Phenylring so entfernt wird, daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 und R_5 OH sind;

2) bei welchem eine Verbindung der allgemeinen Formel


30

35



40 wobei R_1 und R_3 den Festlegungen in Anspruch 1 entsprechen oder eine gemischte Acetalgruppe sind, n der Festlegung aus Anspruch 1 entspricht und OR_8 eine gemischte Acetalgruppe, Benzyloxy- oder Hydroxylgruppe ist, entweder in einer Grignard-Reaktion mit einem Phenyl-Magnesiumhalogenidderivat der allgemeinen Formel

45



oder einer entsprechenden Lithiumverbindung der allgemeinen Formel

50




reagiert wird, wobei R_3 den Festlegungen in Anspruch 1 entspricht oder eine gemischte Acetalgruppe ist, so daß sich ein geschütztes oder ungeschütztes Triphenyldiol der allgemeinen Formel

55

60

65




ergibt, aus welcher Verbindung jede schützende Gruppe R_8 und jede schützende Gruppe in einem Phenylring so entfernt wird, daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 und R_5 OH sind;

3) bei welchem eine Verbindung der allgemeinen Formel (II), bei welcher R_4 und R_5 beide OH sind, so dehydriert wird, daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 und R_5 zusammen eine —O—Brücke zwischen den Kohlenstoffatomen bilden, an welchen sie angegliedert sind;


4) bei welchem eine Verbindung der allgemeinen Formel (II), bei welcher R_4 und R_5 beide OH sind, so dehydriert wird, daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 OH ist;

5) bei welchem die schützende Gruppe R_8 , die nicht Wasserstoff ist, und/oder eine schützende Gruppe in einem Phenylring entfernt wird und eine Verbindung der allgemeinen Formel



wobei R_1 , R_2 und R_3 den Festlegungen aus Anspruch 1 entsprechen oder eine gemischte Acetalgruppe darstellen, n den Festlegungen in Anspruch 1 entspricht und R_8 eine gemischte Acetalgruppe, eine Benzyl-oxy- oder Hydroxylgruppe ist, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 und R_5 zusammen eine —O—Brücke zwischen den Kohlenstoffatomen bilden, an die sie sich angliedern;

6) bei welchem die schützende Gruppe R_8 , die nicht Wasserstoff und/oder eine schützende Gruppe in einem Phenylring ist, entfernt wird und eine Verbindung der allgemeinen Formel



dehydriert wird, bei welcher R_1 , R_2 , R_3 , n und OR_8 den Festlegungen in Schritt 5) entsprechen, so daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_4 OH ist;

7) bei welchem eine Verbindung der allgemeinen Formel (II) im Ring geöffnet wird, bei welcher R_4 und R_5 zusammen eine —O—Brücke zwischen den Kohlenstoffatomen bilden, an die sie sich angliedern, so daß eine Verbindung der allgemeinen Formel (I) entsteht, bei welcher R_4 OH oder ein Halogen ist;

8) bei welchem ein Al-Komplex der allgemeinen Formel



5


10

15

20

wobei R_1 den Festlegungen in Anspruch 1 entspricht und n_1 0 bis 3 ist, reagiert wird mit einem Benzophenonderivat der allgemeinen Formel

25



30

wobei R_2 und R_3 den Festlegungen in Anspruch 1 entsprechen, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 und R_5 OH sind;

9) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher R_4 OH ist, mit einer Carbonsäure mit 1 bis 5 Kohlenstoffatomen oder mit dem entsprechenden Carbonsäurederivat so verestert wird, daß sich eine Verbindung der allgemeinen Formel (I) oder (II) ergibt, bei welcher R_4 eine Formyloxy- oder Alkylcarbonyloxy-Gruppe mit 1 bis 4 Kohlenstoffatomen ist;

35

10) bei welchem eine Verbindung der allgemeinen Formel (II), bei welcher R_5 OH ist, so dehydriert wird, daß sich eine entsprechende Verbindung der allgemeinen Formel (I) ergibt;

11) bei welchem eine Verbindung der allgemeinen Formel (I), bei welcher R_4 eine Formyloxy- oder Alkylcarbonyloxy-Gruppe mit 1 bis 4 Kohlenstoffatomen ist, so hydrolysiert wird, daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_4 OH ist;


40

12) bei welchem eine Verbindung der allgemeinen Formel (II), bei welcher R_4 und R_5 beide OH sind oder zusammen eine —O—Brücke zwischen den Kohlenstoffatomen bilden, an die sie sich angliedern, mit einem Säurekatalysator in einer Carbonsäure mit 1 bis 5 Kohlenstoffatomen reagiert wird, so daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_4 eine Formyloxy- oder Alkylcarbonyloxy-Gruppe mit 1 bis 4 Kohlenstoffatomen ist;

45

13) bei welchem eine Verbindung der allgemeinen Formel

50



55

60


wobei R_1 , R_2 , R_3 , OR_8 und n den in Schritt 1) und 2) gegebenen Festlegungen entsprechen, mit einem geeigneten Säurekatalysator in einer Carbonsäure mit 1 bis 5 Kohlenstoffatomen so reagiert wird, daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_4 eine Formyloxy oder Alkylcarbonyloxy-Gruppe mit 1 bis 4 Kohlenstoffatomen ist;

65

14) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher mindestens eines der Radikale R_1 , R_2 und R_3 eine Alkoxy- oder Aralkoxy-Gruppe ist, so entalkyliert wird, daß sich eine Verbindung der allgemeinen Formel (I) oder (II) ergibt, bei welcher mindestens R_1 , R_2 oder R_3 OH ist;



15) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher R_3 OH ist, mit Diazomethan oder einem Alkylhalogenid-Derivat der allgemeinen Formel



5 alkyliert wird, wobei R_{11} eine Alkylgruppe mit 1 bis 4 Kohlenstoffatomen, eine Benzyl-, Methoxymethyl, 2,3-Dihydroxypropyl-Gruppe oder die Gruppe




15 ist, bei welcher R_6 , R_7 und m den Festlegungen in Anspruch 1 entsprechen, so daß sich eine Verbindung der allgemeinen Formel (I) bzw. (II) ergibt, bei welcher R_3 eine Alkoxygruppe mit 1 bis 4 Kohlenstoffatomen, eine Benzyloxy-Gruppe, Methoxymethoxy- oder 2,3-Dihydroxypropoxy-Gruppe oder die Gruppe




25 ist, bei welcher m , R_6 und R_7 den Festlegungen in Anspruch 1 entsprechen;

16) bei welchem eine Verbindung der allgemeinen Formel (I), bei welcher R_3 OH ist, mit einem Dihaloalkan der allgemeinen Formel



30 alkyliert wird, wobei m den Festlegungen in Anspruch 1 entspricht und die Radikale 'hal' gleiche oder verschiedene Halogenatome sind, so daß sich ein 4-(Haloalkoxy)phenyldiphenylalkan der allgemeinen Formel



45 wobei R_1 , R_2 , R_4 , n , m den Festlegungen in Anspruch 1 entsprechen und hal ein Halogen darstellt, welche anschließend mit einem Amin der allgemeinen Formel




55 reagiert wird, wobei R_6 und R_7 den Festlegungen in Anspruch 1 entsprechen, so daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_3 eine Aminoalkoxy-Gruppe gemäß Anspruch 1 darstellt;

17) bei welchem eine Verbindung der allgemeinen Formel (II), bei welcher R_3 OH ist, mit einem Dihaloalkan der allgemeinen Formel




60 alkyliert wird, wobei m den Festlegungen in Anspruch 1 entspricht und die Radikale hal gleiche oder verschiedene Halogenatome sind, so daß sich ein 4-(Haloalkoxy)phenyldiphenylalkan der allgemeinen Formel





wobei R_1 , R_2 , R_4 , R_5 , n und m den Festlegungen in Anspruch 1 entsprechen und hal ein Halogen ist, worauf die neue Verbindung weiterhin mit einem Amin der allgemeinen Formel



reagiert wird, wobei R_6 und R_7 den vorstehenden Festlegungen entsprechen, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_3 eine Aminoalkoxy-Gruppe nach Anspruch 1 ist;

18) bei welcher die Hydroxylgruppe R_4 in einer Verbindung der allgemeinen Formel (I) oder (II) durch ein Halogen substituiert wird, so daß sich die entsprechende Verbindung der allgemeinen Formel (I) oder (II) ergibt, bei welcher R_4 ein Halogen ist;


19) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher R_4 OH ist, mit Methansulfonsäurechlorid oder Toluolsulfonsäurechlorid so reagiert wird, daß sich eine Verbindung der allgemeinen Formel (I) oder (II) ergibt, bei welcher R_4 eine Mesyloxy- oder Tosyloxy-Gruppe ist;

20) bei welchem die Hydroxylgruppe in einer Verbindung der allgemeinen Formel (II), bei welcher R_4 und R_5 beide OH sind, dehydriert und substituiert werden, so daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_4 ein Halogen ist;


21) bei welchem eine Verbindung der allgemeinen Formel (III), bei welcher R_4 und R_5 beide OH sind, mit Thionylchlorid so behandelt wird, daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_4 Cl ist;

22) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher R_4 eine Mesyloxy- oder Tosyloxy-Gruppe oder ein Halogen ist, durch ein Halogen substituiert wird, so daß sich eine Verbindung der allgemeinen Formel (I) oder (II) ergibt, bei welcher R_4 ein Halogen ist;

23) bei welchem eine Verbindung der allgemeinen Formel



wobei R_1 und R_2 den Festlegungen in Anspruch 1 entsprechen oder eine gemischte Acetalgruppe sind, n den Festlegungen in Anspruch 1 entspricht und hal ein Halogen ist, umgesetzt wird, und zwar entweder in einer Grignard-Reaktion mit einem Phenyl-Magnesiumhalogenid-Derivat oder der entsprechenden Lithiumverbindung gemäß Schritt 1), so daß sich ein Triphenylhydroxyhalogenid der allgemeinen Formel




bildet, aus welchem eine eventuelle schützende Gruppe in einem Phenylring entfernt wird, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 ein Halogen und R_5 eine Hydroxylgruppe ist;

24) bei welchem die gleichen Umsetzungsvorgänge wie in Schritt 23) ausgeführt werden, mit dem Unterschied, daß die Gruppen R_2 und R_3 beim Ausgangsstoffe und beim Reagenz vertauscht sind, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_4 ein Halogen und R_5 eine Hydroxylgruppe ist;


25) bei welchem jede schützende Gruppe in einem Phenylring bei einer Verbindung der allgemeinen Formel (II), bei welcher R_5 OH ist und R_3 den Festlegungen in Schritt 23) entspricht, so dehydriert und entfernt wird, daß sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher R_3 OH und R_4 ein Halogen ist;

26) bei welchem eine Verbindung der allgemeinen Formel




umgesetzt wird, wobei R_1 , R_2 , R_3 und n den Festlegungen in Anspruch 1 entsprechen, Y H oder OH ist, bzw. Z und Y zusammen eine Bindung eingehen, und X ein Halogen beim entsprechenden Grignard-Komplex oder ein Lithiumsalz ist, wobei X MgHal bzw. Li ist, und bei welchem dieser Komplex bzw. dieses Salz mit Formaldehyd, Äthylenoxid oder Trimethylenoxid so reagiert wird, daß sich eine Verbindung der allgemeinen Formel (I) oder (II) bildet, bei welcher R_4 OH und n 1 bis 4 ist;

27) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher n 0 bis 3 und R_4 ein Halogen, eine Mesyloxy- oder Tosyloxy-Gruppe ist, mit einer Cyan-Gruppe so reagiert wird, daß sich ein Triphenylnitril der allgemeinen Formel



bildet, wobei R_1 , R_2 und R_3 den Festlegungen in Anspruch 1 entsprechen, Z und Y den Festlegungen in Schritt 26) entsprechen, und n 0 bis 3 ist, worauf diese neue Verbindung mit der entsprechenden Triphenylcarbonsäure hydrolysiert und die Carbonsäure in einem Arbeitsgang oder über ein Zwischenprodukt reduziert wird, so daß sich eine Verbindung der allgemeinen Formel (I) oder (II) ergibt, bei welcher R_4 OH und n 1 bis 4 ist;

28) bei welchem eine Verbindung der allgemeinen Formel




gemäß Schritt 26), bei welcher X MgHal oder Li ist, mit Kohlendioxid so umgesetzt, daß sich die entsprechende




Triphenylcarbonsäure ergibt, welche abschließend in einem Arbeitsgang oder über ein Zwischenprodukt so reduziert wird, daß sich eine Verbindung der allgemeinen Formel (I) oder (II) ergibt, bei welcher R_4 OH und n 1 bis 4 ist;

29) bei welchem ein geschütztes Diphenyloxaldehyd der allgemeinen Formel




wobei R_1 , R_2 und n den Festlegungen Anspruch 1 entsprechen oder eine gemischte Acetalgruppe sind, und R_{13} und R_{14} , die gleich oder verschieden sein können, Alkylgruppe sind oder zusammen eine 1,3-Propylen-Gruppe bilden, mit einer Verbindung der allgemeinen Formel (I), ergibt, bei welcher CH_2R_4 durch CHO ersetzt ist;

32) bei welchem ein geschützte Triphenylaldehyd der allgemeinen Formel



umgesetzt wird, wobei R_3 den Festlegungen in Anspruch 1 entspricht oder eine gemischte Acetalgruppe und X Mghal oder Li ist, so daß sich ein geschütztes Triphenylhydroxyaldehyd der allgemeinen Formel




ergibt, worauf abschließend die schützende Gruppe und auch jede andere schützende Gruppe in einem Phenylring entfernt wird, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher CH_2R_4 durch CHO ersetzt ist und R_5 OH ist;


30) bei welchem die gleiche Umsetzung wie in Arbeitsschritt 29) ausgeführt wird, wobei allerdings die Gruppen R_2 und R_3 beim Ausgangsstoff und beim Reagenz miteinander vertauscht sind, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher CH_2R_4 durch CHO ersetzt und R_5 OH ist;

31) bei welchem eine Verbindung der allgemeinen Formel






bzw.




oder ein Gemisch aus beiden Verbindungen dehydriert wird, wobei R_1 , R_2 , R_3 und n den Festlegungen in Anspruch 1 entsprechen, woraus sich eine Verbindung der allgemeinen Formel (I) ergibt, bei welcher CH_2R_4 durch CHO ersetzt ist;

32) bei welchem ein geschütztes Triphenylaldehyd der allgemeinen Formel



dehydriert wird, wobei R_1 , R_2 , R_3 , n , R_{13} und R_{14} den Festlegungen in Arbeitsschritt 29 entsprechen, so daß sich eine Verbindung der allgemeinen Formel



ergibt, worauf abschließend die schützende Gruppe aus dieser Verbindung entfernt wird, so daß sich eine Verbindung der allgemeinen Formel (I) bildet, bei welcher anstelle von CH_2R_4 steht;

33) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher R_4 OH ist, zu einer Verbindung der allgemeinen Formel (I) oder (II) oxidiert wird, bei welcher CH_2R_4 durch CHO ersetzt ist;



34) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher R_4 COOH ist, in einem einzigen Arbeitsgang oder über ein Zwischenprodukt zu einer Verbindung der allgemeinen Formel (I) oder (II) reduziert wird, bei welcher CH_2R_4 durch CHO ersetzt ist;


35) bei welchem eine Verbindung der allgemeinen Formel (I) oder eine Verbindung der Formel (II), bei welcher R_5 nicht Wasserstoff ist, hydriert wird, so daß sich eine Verbindung der allgemeinen Formel (II) ergibt, bei welcher R_5 Wasserstoff ist; bzw.

36) bei welchem eine Verbindung der allgemeinen Formel (I) oder (II), bei welcher zumindest eines der Radikale R_1 , R_2 und R_3 OH ist, mit einem entsprechenden Alkylierungsmittel zu einer Verbindung der allgemeinen Formel (I) oder (II) alkyliert wird, bei welcher zumindest eines der Radikale R_1 , R_2 und R_3 eine Alkoxygruppe mit 1 bis 4 Kohlenstoffatomen, eine Benzyloxy- oder Methoxymethoxy-Gruppe ist.


3. Verfahren nach Anspruch 1 oder 2, mit anschließender Trennung der reinen (Z) und der (E)-Isomeren der Verbindung (I) aus dem Isomerengemisch, sowie der reinen (RR,SS)- und (RS,SR)-Enantiomerenpaare der Verbindung (II) aus den entsprechenden Gemischen, durch Kristallisationsdifferentiation, fraktionierte Auflösung, auf chromatographischem Wege oder in einer Kombination aus diesen Verfahren.

Revendications pour les Etats contractants: BE CH DE FR GB IT LI LU NL SE


1. Composé der formule




ou



dans lesquelles n va de 0 à 4; R_1 et R_2 , qui peuvent être identiques ou différents, sont chacun H ou OH; R_3 est H, OH, un halogène, un groupe alcoxy ayant de 1 à 4 atomes de carbone, benzyloxy, méthoxyméthoxy, 2,3-dihydroxypropoxy ou



m étant 1 ou 2, R_6 et R_7 , qui peuvent être identiques ou différents, étant chacun H ou un groupe alkyle contenant de 1 à 4 atomes de carbone, ou




pouvant former un noyau hétérocyclique azoté à trois, quatre, cinq ou six chaînons; R_4 est OH, F, Cl, Br, I, un groupe méthyloxy, tosyloxy, formyloxy, alkylcarbonyloxy ayant de 1 à 4 atomes de carbone ou CH_2R_4 est remplacé par CHO; R_5 est H ou OH; ou bien R_4 et R_5 forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, à condition que



O 095 875

- a) lorsque n est 0, R₂ et R₃ ne soient pas tous les deux en même temps des atomes d'hydrogène,
 b) lorsque n est 0, R₃ soit différent d'un halogène,
 c) lorsque n est 1 et R₄ et R₅ sont chacun OH ou forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, R₁, R₂ et R₃ ne soient pas tous en même temps des atomes d'hydrogène,
 d) lorsque n est 2 et R₄ et R₅ forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, R₁, R₂ et R₃ ne soient pas tous en même temps des atomes d'hydrogène,
 et les sels, N-oxydes et esters non toxiques de celui-ci, acceptables du point de vue pharmacologique, et des mélanges de ceux-ci.

2. Composé selon la revendication 1, dans lequel n est 1 ou 2; R₁, R₂ et R₃ sont chacun un atome d'hydrogène ou un groupe hydroxyle, au moins un des radicaux R₁, R₂ et R₃ étant différent d'un atome d'hydrogène, et R₃ peut en outre être



R₆ et R₇ étant chacun un groupe méthyle ou éthyle; R₄ est un atome de chlore, de brome, ou un hydroxyle; et, dans le cas de la formule II, R₅ est un atome d'hydrogène ou un groupe hydroxyle, ou R₄ et R₅ forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, et les sels et esters non toxiques de celui-ci, acceptables du point de vue pharmacologique, et des mélanges de ceux-ci.

3. 1,2-diphényl-1-(4-hydroxyphényl)butane-1,4-diol, et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

4. 2,3-diphényl-2-(4-hydroxyphényl)tétrahydrofuranne et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

5. 1,2-diphényl-1-(4-méthoxyphényl)-1-butène-4-ol et ses esters.

6. 1,2-diphényl-1-[4-[2-(N,N-diméthylamino)éthoxy]phényl]-1-butène-4-ol et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

7. 2,3-diphényl-2-(4-hydroxyphényl)tétrahydropyranne et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

8. 1,2-diphényl-1-(4-hydroxyphényl)-1-pentène-5-ol et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

9. 4-chloro-1,2-diphényl-1-[4-[2-(N,N-diméthylamino)éthoxy]phényl]-1-butène et ses sels non toxiques acceptables du point de vue pharmacologique.

10. 1-phényl-1,2-bis(4-hydroxyphényl)butane-1,4-diol et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

11. 2-phényl-2,3-bis(4-hydroxyphényl)tétrahydrofuranne et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

12. 1,2-diphényl-1-(4-hydroxyphényl)-1-butène-4-ol et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

13. 4-bromo-1,2-diphényl-1-[4-[2-(N,N-diméthylamino)éthoxy]phényl]-1-butène et ses sels non toxiques acceptables du point de vue pharmacologique.

14. 4-chloro-1,2-diphényl-1-(4-hydroxyphényl)-butane et ses sels et esters non toxiques acceptables du point de vue pharmacologique.

15. 4-chloro-1,2-diphényl-1-(4-hydroxyphényl)-1-butène et ses sels et esters non toxiques acceptables du point de vue pharmacologique.


16. 2,3-diphényl-2-[4-[2-(N,N-diméthylamino)éthoxy]phényl]tétrahydrofuranne et ses sels non toxiques acceptables du point de vue pharmacologique.

17. 1,2-diphényl-1-[4-[2-(N,N-diméthylamino)éthoxy]phényl]butane-1,4-diol et ses sels non toxiques acceptables du point de vue pharmacologique, et ses esters.


18. Composé selon l'une quelconque des revendications 1 à 17 et les sels et esters non toxiques de celui-ci, acceptables du point de vue pharmacologique, à utiliser en thérapeutique dans le traitement de tumeurs hormono-dépendantes.

19. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 17 ou un sel ou un ester non toxique de celui-ci, acceptable du point de vue pharmacologique, et un véhicule pour celui-ci, compatible, acceptable du point de vue pharmacologique.


20. Procédé pour la préparation d'un composé selon la revendication 1, qui comprend la réaction d'un composé de formule



dans laquelle n est tel que défini dans la revendication 1, R'₁ est indentique à R₁ tel que défini dans la revendication 1 ou est un groupe hydroxyle protégé sous forme d'acétal mixte, R'₄ est identique à R₄ tel que défini dans la revendication 1 ou bien est un groupe hydroxyle protégé, et R₉ est un groupe R₂ ou R₃ tel que défini dans la revendication 1 ou bien est un groupe hydroxyle protégé sous forme d'acétal mixte, avec un composé organométallique de formule:




dans laquelle M est -MgHal ou -Li et R₁₀ est un groupe R₂ ou R₃ tel que défini dans la revendication 1 ou bien est un groupe hydroxyle protégé sous forme d'acétal mixte, pour obtenir un composé de formule:




que l'on traite ensuite, si nécessaire, pour transformer les radicaux R'₁, R'₄, R₉ et R₁₀ en radicaux R₁, R₂, R₃ et R₄ afin d'obtenir un composé de formule II dans lequel R₅ est un groupe hydroxyle, et éventuellement la déshydratation du produit pour aboutir à un composé de formule I, ou le traitement du produit pour obtenir un composé de formule II dans lequel R₅ est un atome d'hydrogène, ou un composé dans lequel R₄ et R₅ forment ensemble un pont -O-, et/ou le traitement éventuel du produit pour transformer un radical R₁, R₂, R₃, R₄ ou R₅ en un autre radical tel que défini dans la revendication 1, et/ou le traitement éventuel du produit pour le transformer en un de ses sels, N-oxydes ou esters non toxique, acceptable du point de vue pharmacologique.

21. Procédé pour la préparation d'un composé de formule (II) selon la revendication 1, dans lequel R₄ et R₅ sont chacun OH, qui comprend la réaction d'un complexe d'Al de formule



dans laquelle R₁ est tel que défini dans la revendication 1 et n₁ va de 0 à 3, avec un dérivé de la benzophénone de formule:




dans laquelle R₂ et R₃ sont tels que définis dans la revendication 1.




22. Procédé selon la revendication 20 ou 21 suivi de la séparation des isomères (Z) et (E) purs du composé (I) à partir de mélanges de ceux-ci, ainsi que des couples d'énantiomères (RR,SS) et (RS,SR) purs du composé (II) à partir des mélanges correspondants, par cristallisation fractionnée, dissolution fractionnée, chromatographie ou une combinaison de ces techniques.

Revendications pour l'Etat contractant: AT


1. Procédé pour la préparation d'un composé de formule générale




ou



dans lesquelles n va de 0 à 4; R₁ et R₂, qui peuvent être identiques ou différents, sont chacun H ou OH; R₃ est H, OH, un halogène, un groupe alcoxy ayant de 1 à 4 atomes de carbone, benzyloxy, méthoxyméthoxy, 2,3-dihydroxypropoxy ou




m étant 1 ou 2, R₆ et R₇, qui peuvent être identiques ou différents, étant chacun H ou un groupe alkyle contenant de 1 à 4 atomes de carbone, ou



pouvant former un noyau hétérocyclique azoté à trois, quatre, cinq ou six chaînons; R₄ est OH, F, Cl, Br, I, un groupe méthyloxy, tosyloxy, formyloxy, alkylcarbonyloxy ayant de 1 à 4 atomes de carbone ou CH₂R₄ est remplacé par CHO; R₅ est H ou OH; ou bien R₄ et R₅ forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, à condition que

- lorsque n est 0, R₂ et R₃ ne soient pas tous les deux en même temps des atomes d'hydrogène,
 - lorsque n est 0, R₃ soit différent d'un halogène,
 - lorsque n est 1 R₄ et R₅ sont chacun OH ou forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, R₁, R₂ et R₃ ne soient pas tous en même temps des atomes d'hydrogène,
 - lorsque n est 2 et R₄ et R₅ forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, R₁, R₂ et R₃ ne soient pas tous en même temps des atomes d'hydrogène,
- et des sels, N-oxydes et esters non toxiques de celui-ci, acceptables du point de vue pharmacologique, qui comprend la réaction d'un composé de formule:






5


10 dans laquelle n est tel que défini précédemment, R' est identique à R, tel que défini précédemment ou est un groupe hydroxyle protégé sous forme d'acétal mixte, R' est identique à R, tel que défini précédemment ou bien est un groupe hydroxyle protégé, et R₉ est un groupe R₂ ou R₃ tel que défini précédemment, ou bien est un groupe hydroxyle protégé sous forme d'acétal mixte, avec un composé organométallique de formule:

15



20 dans laquelle M est -MgHal ou -Li et R₁₀ est un groupe R₂ ou R₃ tel que défini précédemment ou est un groupe hydroxyle protégé sous forme d'acétal mixte, pour aboutir à un composé de formule:

25



30

35

que l'on traite ensuite, si nécessaire, pour transformer les radicaux R' , R' , R₉ et R₁₀ en radicaux R₁, R₂, R₃ et R₄ afin d'obtenir un composé de formule II dans lequel R₅ est un groupe hydroxyle, et éventuellement la déshydratation du produit pour obtenir un composé de formule I, ou le traitement du produit pour obtenir un composé de formule II dans lequel R₅ est un atome d'hydrogène ou un composé dans lequel R₄ et R₅ forment ensemble un pont —O—, et/ou le traitement éventuel du produit pour transformer un radical R₁, R₂, R₃, R₄ ou R₅ en un autre radical tel que défini précédemment, et/ou le traitement éventuel du produit pour le transformer en un de ses sels, N-oxydes ou esters non toxique, acceptable du point de vue pharmacologique.


40

2. Procédé selon la revendication 1, qui comprend

45

1) la réaction d'un composé de formule


50



55

60 dans laquelle R₁ et R₂ sont tels que définis dans la revendication 1 ou sont des acétals mixtes, n est tel que défini dans la revendication 1 et OR₈ est un acétal mixte, un groupe benzyloxy ou hydroxyle, soit par une réaction de Grignard avec un dérivé d'halogénure de phénylmagnésium de formule


65




60



soit avec un composé lithié correspondant de formule




dans laquelle R_3 est tel que défini dans la revendication 1 ou un groupement acétal mixte, pour obtenir un triphényldiol protégé ou non protégé de formule




dont on élimine tout groupe protecteur R_8 et tout groupe protecteur dans un noyau phényle, pour obtenir un composé de formule (II) dans lequel R_4 et R_5 sont chacun OH;


2) la réaction d'un composé de formule




dans laquelle R_1 et R_3 sont tels que définis dans la revendication 1 ou des acétals mixtes, n est tel que défini dans la revendication 1 et OR_8 est un acétal mixte, un groupe benzyloxy ou hydroxyle, soit par une réaction de Grignard avec un dérivé d'halogénure de phénylmagnésium de formule



soit avec un composé lithié correspondant de formule



dans laquelle R_2 est tel que défini dans la revendication 1 ou est un acétal mixte, pour aboutir à un triphényldiol protégé ou non protégé de formule




dont on élimine tout groupe protecteur R_6 et tout groupe protecteur dans un noyau phényle pour obtenir un composé de formule (II) dans lequel R_4 et R_5 sont chacun OH;

3) la déshydratation d'un composé de formule (II) dans lequel R_4 et R_5 sont chacun OH, pour aboutir à un composé de formule (II) dans lequel R_4 et R_5 forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés;


4) la déshydratation d'un composé de formule (II) dans lequel R_4 et R_5 sont chacun OH, pour aboutir à un composé de formule (II) dans lequel R_4 est OH;

5) l'élimination du groupe protecteur R_6 , qui est différent d'un atome d'hydrogène, et/ou du groupe protecteur dans un noyau-phényle, et la déshydratation d'un composé de formule



dans laquelle R_1 , R_2 et R_3 sont tels que définis dans la revendication 1 ou sont des acétals mixtes, n est tel que défini dans la revendication 1 et OR_6 est un acétal mixte, un groupe benzyloxy ou hydroxyle, pour aboutir à un composé de formule (II) dans lequel R_4 et R_5 forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés;

6) L'élimination du groupe protecteur R_6 , qui est différent d'un atome d'hydrogène, et/ou d'un groupe protecteur dans un noyau phényle, et la déshydratation d'un composé de formule




dans laquelle R_1 , R_2 , R_3 , n et OR_6 sont tels que définis dans l'étape 5), pour aboutir à un composé de formule (I) dans lequel R_4 est OH;


7) l'ouverture du cycle d'un composé de formule (II) dans lequel R_4 et R_5 forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, pour aboutir à un composé de formule (I) dans lequel R_4 est OH ou un halogène;

8) la réaction d'un complexe d'Al de formule





dans laquelle R_1 est tel que défini dans la revendication 1 et n_1 va de 0 à 3, avec un dérivé de la benzo-phénone de formule



30 dans laquelle R_2 et R_3 sont tels que définis dans la revendication 1, pour aboutir à un composé de formule (II) dans lequel R_4 et R_5 sont chacun OH;


9) l'estérification d'un composé de formule (I) ou (II) dans lequel R_4 est OH, avec un acide carboxylique ayant de 1 à 5 atomes de carbone, ou avec le dérivé d'acide carboxylique correspondant, pour obtenir un composé de formule (I) ou (II) dans lequel R_4 est un groupe formyloxy ou alkylcarbonyloxy ayant de 1 à 4 atomes de carbone;

10) la déshydratation d'un composé de formule (II) dans lequel R_5 est OH, pour obtenir un composé correspondant de formule (I);

11) l'hydrolyse d'un composé de formule (I) dans lequel R_4 est un groupe formyloxy ou alkylcarbonyloxy ayant de 1 à 4 atomes de carbone, pour aboutir à un composé de formule (I) dans lequel R_4 est OH;

12) la réaction d'un composé de formule (II) dans lequel R_4 et R_5 sont chacun OH ou forment ensemble un pont —O— entre les atomes de carbone auxquels ils sont liés, avec un catalyseur acide dans un acide carboxylique contenant de 1 à 5 atomes de carbone, pour aboutir à un composé de formule (I) dans lequel R_4 est un groupe formyloxy ou alkylcarbonyloxy ayant de 1 à 4 atomes de carbone;

13) la réaction d'un composé de formule



dans laquelle R_1 , R_2 , R_3 , OR_8 et n sont tels que définis dans l'étape 1) ou 2), avec un catalyseur acide approprié dans un acide carboxylique contenant de 1 à 5 atomes de carbone, pour aboutir à un composé de formule (I) dans lequel R_4 est un groupe formyloxy ou alkylcarbonyloxy ayant de 1 à 4 atomes de carbone;




14) la désalkylation d'un composé de formule (I) ou (II) dans lequel au moins un des radicaux R_1 , R_2 et R_3 est un radical alcoxy ou aralcoxy, pour aboutir à un composé de formule (I) ou (II) dans lequel au moins un des radicaux R_1 , R_2 et R_3 est OH.


15) l'alkylation d'un composé de formule (I) ou (II) dans lequel R_3 est OH, avec le diazométhane ou un dérivé de type halogénure d'alkyle de formule



dans laquelle R_{11} est un groupe alkyle ayant de 1 à 4 atomes de carbone, benzyle, méthoxyméthyle, 2,3-dihydroxypropyle ou




R_6 , R_7 et m étant tels que définis dans la revendication 1, pour aboutir à un composé de formule (I) ou (II) dans lequel R_3 est un groupe alcoxy ayant de 1 à 4 atomes de carbone, benzyloxy, méthoxyméthoxy, 2,3-dihydroxypropoxy ou




m , R_6 et R_7 étant tels que définis dans la revendication 1;


16) l'alkylation d'un composé de formule (I) dans lequel R_3 est OH, avec un dihalogéno-alcane de formule



dans laquelle m est tel que défini dans la revendication 1 et les radicaux hal sont des atomes d'halogène qui peuvent être identiques ou différents, pour aboutir à un 4-(halogénoalcoxy)phényldiphénylalcane de formule:



dans laquelle R_1 , R_2 , R_4 et n et m sont tels que définis dans la revendication 1 et hal est un halogène, que l'on fait réagir à nouveau avec une amine de formule:




dans laquelle R_6 et R_7 sont tels que définis dans la revendication 1, pour aboutir à un composé de formule (I) dans lequel R_3 est un groupe amino-alcoxy tel que défini dans la revendication 1;


17) l'alkylation d'un composé de formule (II) dans lequel R_3 est OH, avec un dihalogéno-alcane de formule



dans laquelle m est tel que défini dans la revendication 1 et les radicaux hal sont des atomes d'halogène qui peuvent être identiques ou différents, pour aboutir à un 4-(halogénoalcoxy)phényldiphénylalcane de formule:



dans laquelle R₁, R₂, R₄, R₅, n, m sont tels que définis dans la revendication 1 et hal est un halogène, que l'on fait réagir à nouveau avec une amine de formule



dans laquelle R₆ et R₇ sont tels que définis plus haut, pour aboutir à un composé de formule (II) dans lequel R₃ est un groupe amino-alcoxy tel que défini dans la revendication 1;

18) le remplacement du groupe hydroxyle R₄ dans un composé de formule (I) ou (II) par un halogène, pour aboutir au composé correspondant de formule (I) ou (II) dans lequel R₄ est un halogène;


19) la réaction d'un composé de formule (I) ou (II), dans lequel R₄ est OH, avec le chlorure d'acide méthanesulfonique ou le chlorure d'acide toluènesulfonique, pour aboutir à un composé de formule (I) ou (II) dans lequel R₄ est un groupe méthyloxy ou tosyloxy;

20) la déshydratation, et le remplacement du groupe hydroxyle d'un composé de formule (II) dans lequel R₄ et R₅ sont chacun OH, pour aboutir à un composé de formule (I) dans lequel R₄ est un halogène;

21) le traitement par le chlorure de thionyle d'un composé de formule (II) dans lequel R₄ et R₅ sont chacun OH, pour obtenir un composé de formule (I) dans lequel R₄ est Cl;


22) la substitution par un halogène d'un composé de formule (I) ou (II) dans lequel R₄ est un groupe méthyloxy, tosyloxy ou halogéno, pour aboutir à un composé de formule (I) ou (II) dans lequel R₄ est un halogène;

23) la réaction d'un composé de formule:



dans laquelle R₁ et R₂ sont tels que définis dans la revendication 1 ou sont des acétals mixtes, n est tel que défini dans la revendication 1 et hal est un halogène, soit par une réaction de Grignard avec un dérivé d'halogénure de phénylmagnésium, soit avec le composé lithié correspondant tel que défini dans l'étape 1), pour obtenir un triphénylhydroxyhalogénure de formule:






15 dont on élimine un groupe protecteur éventuellement présent dans un noyau phényle, pour aboutir à un composé de formule (II) dans lequel R_4 est un halogène et R_5 est un groupe hydroxyle;

24) la mise en oeuvre des mêmes réactions que dans l'étape 23), mis à part que les radicaux R_2 et R_3 du produit de départ et du réactif sont interchangeés, pour aboutir à un composé de formule (II) dans lequel R_4 est un halogène et R_5 est un groupe hydroxyle;


20 25) la déshydratation, et l'élimination de tout groupe protecteur dans un noyau phényle, d'un composé de formule (II) dans lequel R_5 est OH et R_3 est tel que défini dans l'étape 23), pour aboutir à un composé de formule (I) dans lequel R_3 est OH et R_4 est un halogène;

26) la transformation d'un composé de formule:



35 dans laquelle R_1 , R_2 , R_3 et n sont tels que définis dans la revendication 1, Z est H, Y est H ou OH, ou Z et Y forment ensemble une liaison, et X est un halogène, en complexe de Grignard ou en sel de lithium correspondant, dans lequel X est respectivement MgHal ou Li , et la mise en réaction de ce complexe ou de ce sel avec le formaldéhyde, l'oxyde d'éthylène ou l'oxyde de triméthylène, pour aboutir à un composé de formule (I) ou (II) dans lequel R_4 est OH et n va de 1 à 4;


27) la réaction d'un composé de formule (I) ou (II) dans lequel n va de 0 à 3 et R_4 est un halogène, un groupe mésoxy ou tosyloxy, avec un groupe cyano pour aboutir à un triphénylnitrile de formule:



50 dans laquelle R_1 , R_2 et R_3 sont tels que définis dans la revendication 1, Z et Y sont tels que définis dans l'étape 26) et n va de 0 à 3, l'hydrolyse de ce composé conduisant à l'acide triphénylcarboxylique correspondant, et la réduction dudit acide carboxylique en une étape ou en passant par un composé intermédiaire, pour obtenir un composé de formule (I) ou (II) dans lequel R_4 est OH et n va de 1 à 4;


28) la transformation par l'anhydride carbonique d'un composé de formule






tel que définie dans l'étape 26), dans lequel X est Mghal ou Li, pour aboutir à l'acide triphénylcarboxylique correspondant qui est finalement réduit, en une étape ou en passant par un composé intermédiaire, pour aboutir à un composé de formule (I) ou (II) dans lequel R₄ est OH et n va de 1 à 4;


29) la réaction d'un diphenyloxo-aldéhyde protégé de formule:



dans laquelle R₁, R₂ sont tels que définis dans la revendication 1 ou sont des acétals mixtes, n est tel que défini dans la revendication 1, et R₁₃ et R₁₄, qui pouvant être identiques ou différents, sont des groupes alkyle ou forment ensemble un groupe 1,3-propylène, avec un composé de formule



dans laquelle R₃ est tel que défini dans la revendication 1 ou est un acétal mixte, et X est Mghal ou Li, pour aboutir à un triphénylhydroxy-aldéhyde protégé de formule:




(XXXIX)

et finalement l'élimination du groupe protecteur, et également de tout groupe protecteur présent dans un noyau phényle, pour aboutir à un composé de formule (II) dans lequel CH₂R₄ est remplacé par CHO et R₅ est OH;




30) la mise en oeuvre de la même réaction que dans l'étape 29), mis à part que les groupes R_2 et R_3 du produit de départ et du réactif sont interchangés, pour aboutir à un composé de formule (II) dans lequel CH_2R_4 est remplacé par CHO et R_5 est OH;

31) la déshydratation d'un composé de formule:




ou




ou d'un mélange desdits composés dans lesquels R_1 , R_2 , R_3 et n sont tels que définis dans la revendication 1, pour aboutir à un composé de formule (I) dans lequel CH_2R_4 est remplacé par CHO;

32) la déshydratation d'un triphénylaldéhyde protégé de formule:



dans laquelle R_1 , R_2 , R_3 , n , R_{13} et R_{14} sont tels que définis dans l'étape 29), pour obtenir un composé de formule:



et finalement l'élimination du groupe protecteur de ce composé, pour aboutir à un composé de formule (I) dans lequel CH_2R_4 est remplacé par CHO;

33) l'oxydation d'un composé (I) ou (II) dans lequel R_4 est OH, pour obtenir un composé de formule (I) ou (II) dans lequel CH_2R_4 est remplacé par CHO;

5 34) la réduction d'un composé de formule (I) ou (II) dans lequel R_4 est COOH , en une seule étape ou en passant par un composé intermédiaire, pour aboutir à un composé de formule (I) ou (II) dans lequel CH_2R_4 est remplacé par CHO;

35) l'hydrogénation d'un composé de formule (I) ou d'un composé de formule (II) dans lequel R_5 est différent d'un atome d'hydrogène, pour aboutir à un composé de formule (II) dans lequel R_5 est H; ou

10 36) l'alkylation d'un composé de formule (I) ou (II) dans lequel au moins un des radicaux R_1 , R_2 et R_3 est OH, avec un agent d'alkylation approprié, pour aboutir à un composé de formule (I) ou (II) dans lequel au moins un des radicaux R_1 , R_2 et R_3 est un radical alcoxy ayant de 1 à 4 atomes de carbone, benzyloxy ou méthoxyméthoxy.

15 3. Procédé selon la revendication 1 ou 2, suivi de la séparation des isomères (Z) et (E) purs du composé (I) à partir de mélanges de ceux-ci, ainsi que des couples d'énantiomères (RR,SS) et (RS,SR) purs du composé (II) à partir des mélanges correspondants, par cristallisation fractionnée, dissolution fractionnée, chromatographie ou une combinaison de ces techniques.

20

25

30

35

40

45

50

55

60

65

